



(51) International Patent Classification:

A61N 5/00 (2006.01) A61N 2/00 (2006.01)
A61B 18/18 (2006.01)

(21) International Application Number:

PCT/US2010/030010

(22) International Filing Date:

5 April 2010 (05.04.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/211,879 3 April 2009 (03.04.2009) US

(71) Applicant (for all designated States except US): **PALOMAR MEDICAL TECHNOLOGIES, INC.** [US/US]; 15 Network Drive, Burlington, MA 01803 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALTSHULER, Gregory, B.** [US/US]; 17 Cerulean Way, Lincoln, MA 01773 (US). **BELIKOV, Andrei** [RU/RU]; 141 Narodnogo Opolcheniya, #86, St. Petersburg, 198217 (RU). **CHILDS, James, J.** [US/US]; 50 Meadow Road, Bolton, MA 01740 (US). **EROFEEV, Andrei, V.** [RU/US]; 61 Wesley Street, North Andover, MA 01845 (US). **YAROSLAVSKY, Ilya** [RU/US]; 12 Farnum Street, North Andover, MA 01845 (US). **ZENZIE, Henry, H.** [US/US]; 14 Whiting Road, Dover, MA 02030 (US).

[Continued on next page]

(54) Title: METHOD AND APPARATUS FOR TREATMENT OF TISSUE

(57) Abstract: Devices and methods of treatment of tissue, such as skin tissue, with electromagnetic radiation (EMR) are disclosed that employ local deformation of tissue in small areas. Devices and methods employing local deformation are used to produce fractional lattices of EMR-treated islets in tissue for application including hair growth management.




FIG. 1B



FIG. 1C



FIG. 1D



FIG. 1E



FIG. 1F



FIG. 1G



FIG. 1H




FIG. 1I




FIG. 1J




FIG. 1K



FIG. 1L





(74) **Agents:** ENGELLENER, Thomas, J. et al.; Nutter McClellenn & Fish LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210-2604 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

METHOD AND APPARATUS FOR TREATMENT OF TISSUERELATED APPLICATIONS

5 This application claims priority to U.S. Provisional Application Ser. No. 61/211,879 filed on April 3, 2009, entitled "Method and Apparatus for Fractional Treatment of Hair with Directed Energy"; and is a continuation-in-part of U.S. Patent Application No. 12/405,931 filed March 17, 2009, entitled "Method and Apparatus for Fractional Deformation and Treatment of Tissue," which claims priority to U.S. Provisional Application Ser. No. 61/069,678 filed March 17, 2008, entitled "Method and Apparatus for Fractional Deformation and Treatment of Tissue," U.S. Provisional Application Ser. No. 61/188,339 filed August 8, 2008, entitled "Method and Apparatus for Fractional Deformation and Treatment of Tissue," and U.S. Provisional Application Ser. No. 61/198,272 filed November 3, 2008, entitled "Combined Fractional Ablative and Fractional Non-Ablative Treatment." This application incorporates by reference each of the above applications to which it claims priority in its entirety.

Background of the Invention

20 Hair can be treated to manage hair growth and/or for the removal of existing hairs. Methods of treating hair with directed energy utilize selective absorption of light by portions of the hair structure (e.g., melanin in hair structures). Current hair management methods emphasize the importance of uniform coverage of the treatment area (e.g., no-gaps in coverage of the treatment area) in order to achieve the desired aesthetic effect (e.g., hair growth management and/or hair removal) in a minimal number of treatment sessions and in order to efficiently use the directed energy.

Field of the Invention.

30 The devices and methods disclosed herein relate to the treatment of soft and hard tissues with electromagnetic energy generally, including, without limitation, optical energy having wavelengths in the ultraviolet, visible and infrared ranges. More specifically, the devices and methods disclosed herein relate to the treatment of tissue with electromagnetic radiation (EMR) in conjunction with local deformation of tissue in small areas. Also disclosed are devices and systems for producing lattices of EMR-

treated islets in tissue, and cosmetic and medical applications of such devices and systems.

5 Description of the Related Art

Electromagnetic radiation, particularly in the form of laser light, has been used in a variety of cosmetic and medical applications, including uses in dermatology, dentistry, ophthalmology, gynecology, otorhinolaryngology and internal medicine. For most dermatological applications, the EMR treatment can be performed with a device that
10 delivers the EMR to the surface of the targeted tissues. For applications in internal medicine, the EMR treatment is typically performed with a device that works in combination with an endoscope or catheter to deliver the EMR to internal surfaces and tissues.

As a general matter, existing EMR treatments are typically designed to (a)
15 deliver one or more particular wavelengths (or a range (or ranges) of wavelengths) of EMR to a tissue to induce a particular chemical reaction, (b) deliver EMR energy to a tissue to cause an increase in temperature, or (c) deliver EMR energy to a tissue to damage or destroy cellular or extra cellular structures, such as for skin remodeling.

For skin remodeling, absorption of optical energy by water is widely used in two
20 approaches: ablative skin resurfacing, typically performed with either CO₂ (10.6μm) or Er:YAG (2.94 μm) lasers, and non-ablative skin remodeling using a combination of deep skin heating with light from Nd:YAG (1.34 μm), Er:glass (1.56μm) or diode laser (1.44μm) and skin surface cooling for selective damage of sub-epidermal tissue. Ablative skin resurfacing generally employs a wavelength range of from about 2600 nm
25 to about 11000 nm. Non-ablative skin treatments generally employ a wavelength range of from about 290 nm to about 2600 nm. Non-ablative techniques offer considerably reduced risk of side effects and are much less demanding on post-operative care. However, clinical efficacy of the non-ablative procedures has not been satisfactory.

In the cosmetic field for the treatment of various skin conditions, alternative
30 methods and devices have been developed that irradiate or cause damage in a portion of the tissue area and/or volume being treated. These methods and devices have become known as fractional technology. Fractional technology is thought to be a safer method of treatment of skin for cosmetic purposes, because tissue damage occurs within smaller

- 3 -

sub-volumes or islets within the larger volume of tissue being treated. The tissue surrounding the “treated” and/or “damaged” islets is spared from the damage. Because the resulting islets are surrounded by neighboring healthy tissue (i.e., neighboring untreated tissue) the healing process is thorough and fast. Furthermore, it is believed that the surrounding healthy tissue aids in healing and the treatment effects of the damaged tissue.

Examples of devices that have been used to treat the skin using non-ablative procedures such as skin resurfacing include the Palomar® 1540 Fractional Handpiece, the Reliant Fraxel® SR Laser and similar devices by ActiveFX, Alma Lasers, Iridex, and Reliant Technologies. Examples of devices that have been used to treat the skin using ablative procedures include the Palomar® 2940 Fractional Handpiece, for example. Methods and devices for fractional non-ablative and fractional ablative treatment are disclosed in US Patent Publication No. US2008/0172047A1, USSN 11/966,468, filed Dec. 28, 2007; in US Patent No. 6,997,923, USSN 10/033,302, filed Dec. 27, 2001 and related family member applications, and the contents of all of these applications are incorporated by reference herein.

Although fractional technology is presently thought to be superior to other EMR-based technologies for many applications, the fractional application of EMR can be made more efficient and effective.

SUMMARY

For example, in many applications, the depth of penetration of the fractional columns into the tissue is believed to be important to the effectiveness of the treatment.

In applications where depth of penetration into human skin is important, a deeper column capable of reaching deeper into the dermis of the tissue or even to the hypodermis will result in greater effectiveness of the treatment. However, fractional columns have generally been made deeper by applying more energy, which has other ramifications, including cost of the device and the application of more power to the tissue which can result in more damage (e.g., collateral damage, unintended damage and/or undesirable damage) to the tissue and the diffusion of additional heat within the tissue. Similarly, in other applications, a shallower depth that can be achieved using less

energy will allow a device to use less energy, a less costly EMR source and/or the application of less energy per volume of tissue.

5 By developing additional devices and methods to more efficiently deliver EMR in a fractional treatment, the fractional devices and treatments can be further optimized and improved. For example, deeper treatment columns can be created, less costly light sources could be used, more energy efficient devices could be created, zones of damage could be created at the same depth using less energy per unit of volume, and/or more effective treatments could be created. The present disclosure depends, in part, upon the
10 discovery that, by deforming tissue in a small area, the tissue can be treated more effectively and/or that a device or treatment can be more efficient or otherwise optimized. In particular, when a small area of tissue is deformed by applying pressure to the area and a beam of EMR is applied to the deformed area, the penetration of the EMR into the tissue is greater than the penetration of the same beam of EMR into tissue that is
15 not so deformed. More specifically, the depth of the damage from the EMR beam applied to deformed tissue is deeper than the depth of the damage from the EMR beam when applied to relaxed tissue (tissue that was not deformed or that is no longer deformed). This phenomenon can be used, in particular, to improve existing fractional treatments of tissue with EMR and to develop new such treatments. However, the
20 principle is also applicable to non-fractional treatments, where the deformation of a number of small areas of tissue can be used to improve the penetration of the effect of EMR in non-fractional applications that treat a relatively larger area relative to the size deformed areas.

25 Downtime is the time associated with a procedure in which a patient can not or chooses to not resume normal activities as a result of the procedure. Fractional non-ablative techniques require little to no downtime relative to Fractional ablative techniques which results in an appearance (e.g., bleeding and/or oozing) that can require a few days of downtime. However, fractional non-ablative techniques generally require multiple treatments to achieve clinically desirable outcomes.

30 In one aspect, the disclosure relates to an apparatus for performing a treatment on a tissue (e.g., skin, subcutaneous tissue such as fat and/or muscle). A treatment device has an electromagnetic radiation source and is configured to deliver electromagnetic radiation. The apparatus includes an applicator (e.g., a deformation application) for

- 5 -

creating point compression of tissue. The electromagnetic radiation source is in communication with the applicator, which has one or more point compression elements. The one or more point compression elements each has a contact compression surface.

5 The applicator is configured to deliver an electromagnetic radiation beam into the tissue through the contact compression surface during operation. The contact compression surface has a size larger than the electromagnetic radiation beam delivered therethrough. In one embodiment, at least a portion of the applicator is cooled (e.g., to below external skin temperature and/or to below tissue temperature). Alternatively or in addition, at
10 least a portion of the one or more point compression elements is cooled. At least a portion of the one or more point compression elements may be transparent to electromagnetic radiation (e.g., made from a transparent material such as sapphire).

Each contact compression surface of the point compression element(s) has an outer perimeter and an inner perimeter. In one embodiment of the apparatus, the
15 applicator is configured to deliver the electromagnetic radiation beam solely through an inner perimeter of the contact compression surface. In some embodiments, the one or more point compression elements form an array and the distance between adjacent point compression elements is substantially constant. Optionally, the portion of one contact compression surface that delivers the electromagnetic radiation beam is a substantially
20 constant distance from the portion of an adjacent contact compression surface that delivers the electromagnetic radiation beam. In some embodiments, the applicator is configured to deliver the electromagnetic radiation beam through the contact compression surface such that the distance between adjacent electromagnetic radiation beams is substantially constant. In addition, the distance between adjacent point
25 compression elements may be substantially constant.

In some embodiments, at least one dimension of the contact compression surface of the one or more point compression element(s) is less than about 3 mm. In some embodiments, the distance between adjacent point compression elements is greater than the two times smallest dimension of the contact compression surface. Optionally, the
30 distance between adjacent point compression elements is greater than the three times smallest dimension of the contact compression surface. In one embodiment, the point compression element is a cylindrical groove and the smallest dimension of the contact compression surface can be several order of magnitude smaller than the largest

dimension of the cylindrical grooves contact compression surface (e.g., the surface that forms the line-like appearance). In some embodiments, at least one dimension of the contact compression surface is no more than twice the desired depth of tissue treatment.

5 In one embodiment, the one or more point compression elements each have a collocated electromagnetic radiation beam. When an electromagnetic beam is collocated in a point compression element it is delivered through the center of the point compression element. Where an electromagnetic beam is collocated in a contact compression surface of a point compression element, the electromagnetic beam is
10 delivered through the center of the contact compression surface. In some embodiments, the distance between adjacent electromagnetic radiation beams (e.g., collocated electromagnetic radiation beams) is substantially the same.

 In some embodiments, the apparatus (e.g., the applicator) includes a mechanical implement that applies pressure to the one or more point compression elements. The
15 applied pressure can be up to about 50 Newtons/cm², for example. In another embodiment, the apparatus (e.g., the applicator) also includes a transducer that provides a signal when a desired compression of tissue is reached. The signal can be, for example, audio (e.g., a buzzing or other sound indicating a certain compression has been achieved), and/or visual (e.g., a light or a dial of measurement including the compression
20 level that has been achieved). The transducer can be mechanical, electromechanical, and/or electrical, for example. In some embodiments, the desired compression of tissue is up to 50 Newtons/cm² and at this level the signal is provided to the user.

 In some embodiments, the apparatus has a source of electromagnetic radiation with a wavelength range of from about 290 nm to about 11000 nm, a fluence of from
25 about 0.1 J/cm² to about 1000 J/cm², a pulse width of from about 1 nanosecond to continuous wave, and a radiation beam with a spot size of from about 50 microns to about 3 mm.

 In another aspect, the disclosure relates to a method for treating a region of tissue (e.g., skin, subcutaneous tissue such as fat and/or muscle). The method includes
30 pressing a contact compression surface of one or more point compression elements to a skin surface and applying electromagnetic radiation through the one or more contact compression surfaces and each of the one or more contact compression surfaces has a size larger than the size of the electromagnetic radiation beam delivered therethrough.

- 7 -

In one embodiment of the method, the electromagnetic radiation beam causes at least one of thermal, chemical, and mechanical effects on the region of tissue. In another embodiment, the method includes applying two or more pulses of electromagnetic radiation without removing the one or more point compression elements from the skin surface between applied pulses (i.e., stacking of pulses).

In another embodiment of the method, the contact compression surface of one or more point compression elements is pressed to a skin surface to displace tissue fluid from the compressed tissue (e.g., the tissue compressed under the contact compression surface of the point compression element). The tissue fluid can include at least one of water, blood, and lymph.

In another embodiment of the method, electromagnetic radiation is applied through the one or more contact compression surfaces, wherein each of the one or more contact compression surfaces has a size larger than the size of the electromagnetic radiation beam delivered therethrough and wherein the electromagnetic radiation is delivered to at least a portion of the compressed tissue where tissue fluid is displaced due to compression by the contact compression surface of the point compression element. In some embodiments, the contact compression surface of one or more point compression elements is pressed to a skin surface for at least 1 second or for at least three seconds. The length of time that the point compression element is pressed to the skin surface can depend on the size of the point compression element and more particularly the size of the contact compression point, with a smaller size requiring less time for fluid displacement than a larger size pressed on the same tissue region.

In some embodiments, the method includes applying electromagnetic radiation through the one or more contact compression surfaces, the electromagnetic radiation source is in communication with an applicator, and the one or more point compression elements are disposed on the applicator, wherein each of the one or more contact compression surfaces has a size larger than the size of the electromagnetic radiation beam delivered therethrough. The method can also include cooling at least a portion of the skin surface (e.g., the tissue and/or of the subcutaneous tissue such as fat and/or muscle) with one or more point compression elements. In other embodiments, the method also includes cooling at least a portion of the skin surface with the applicator.

In some embodiments, at least one dimension of the one or more contact compression surface is no more than three times greater than the desired depth of tissue treatment (the tissue being treated can include skin, and subcutaneous tissue such as fat and/or muscle). In some embodiments, the treatment depth ranges from about 0.1 mm to about 10 mm or from about 0.1 mm to about 3 mm. In one embodiment, the surface area of the one or more contact compression surfaces is no more than 30% of the surface of the region of tissue being treated. It is desirable that the region of tissue being treated not be clustered together and rather be dispersed over the region of tissue. In some
5
10
15
20
25
30
embodiments, at least one dimension of the one or more contact compression surface is no more than the desired depth of tissue treatment.

In some embodiments, at least a portion of each of the one or more point compression elements is transparent to electromagnetic radiation (e.g., made from a transparent material such as sapphire).

In some embodiments, the one or more point compression elements form an array and the distance between the centers of adjacent point compression elements is substantially constant and electromagnetic radiation is applied through the center of the one or more contact compression surfaces such that the distance between adjacent electromagnetic radiation beams is substantially constant. In addition each of the one or
15
20
25
30
more contact compression surfaces has a size larger than the size of the electromagnetic radiation beams delivered therethrough. In some embodiments, the one or more point compression elements each has a collocated electromagnetic radiation beams. Optionally, the distance between adjacent electromagnetic radiation beams is substantially the same.

In one embodiment, the method employs electromagnetic radiation with a wavelength range of from about 290 nm to about 11000 nm, a fluence of from about 0.1 J/cm² to about 1000 J/cm², a pulse width of from about 1 nanosecond to continuous wave, and a radiation beam with a spot size of from about 50 microns to about 3 mm. The one or more point compression elements can have a depth of deformation (into the region of tissue in which they are pressed) that ranges from about 100 microns to about 3 mm at the deepest point of deformation relative to the normal surface of the skin surface. In some embodiments, the method includes receiving a signal when a desired compression is reached. The desired compression is up to 50 Newtons/cm².

In another aspect, the disclosure relates to a method for treating a volume of a patient's skin by irradiating portions of the volume. The method includes providing a first source for generating non-ablative treatment radiation and delivering a non-ablative treatment radiation to selected treatment regions in the volume to a depth of up to 2 mm such that following application of the non-ablative treatment the ratio of the non-ablative treatment regions to the volume is from about 1% to about 75%. The first source for generating non-ablative treatment radiation can have a wavelength of from about 900 nm to about 2600 nm. The method also includes providing a second source for generating ablative treatment radiation and delivering, subsequent to the non-ablative treatment radiation, an ablative treatment radiation to selected treatment regions in the volume to a depth of up to 400 microns such that following application of the ablative treatment the ratio of the ablative treatment regions to the volume is from about 1% to about 75% and wherein both the non-ablative treatment regions and the ablative treatment regions are separated by untreated tissue. The second source for generating ablative treatment radiation can have a wavelength of from about 2600 to about 11000. The method can optionally include pressing a contact compression surface of one or more point compression elements to a skin surface and applying at least one of the non-ablative treatment radiation and the ablative treatment radiation through the one or more contact compression surfaces. In one embodiment, the volume of non-ablative treatment is greater than the volume of ablative treatment.

In another aspect, the disclosure relates to a method for treating a volume of a patient's skin by irradiating portions of the volume. In accordance with the method a single source for generating non-ablative treatment radiation and ablative treatment radiation is provided. Both non-ablative treatment radiation and ablative treatment radiation are delivered in a first selected treatment region within said volume such that following application of both non-ablative treatment radiation and ablative treatment radiation the first treatment region is separated by untreated tissue within said volume. In some embodiments, the pulses of non-ablative and ablative treatment radiation are stacked in the first selected treatment region.

Devices and methods of producing islets and/or islands and/or columns of treatment (e.g., damage) are disclosed. Such treatments can permit various therapeutic treatments on a patient's body at depths up to approximately 4 mm. Formation of islands

- 10 -

and/or columns of damage in three dimensions facilitates healing (by permitting continued blood flow and cell proliferation between skin layers and islands of damage and in the untreated regions of a volume of treated tissue). In this way patient discomfort may be reduced. In addition, the fractional approach permits targeting of specific components for treatment without damage to surrounding parts of the patient's body, thereby more efficiently using the applied radiation while also reducing peripheral damage to the patient's body as the result of such treatment. The wavelengths utilized for treatment can be selected for the desired depth of treatment, rather than being restricted to a wavelength optimally absorbed by a targeted chromophore. In fact, while the wavelengths selected normally have significant water absorption, it is desirable that the selected wavelengths is that they are not highly absorbed, even by water, so that the radiation can reach desired depths without losing substantial energy/photons to absorption. The concentration of photons/energy at treatment columns increases energy at these portions more than enough to compensate for reduced absorption at the wavelength utilized.

Any of a number of cosmetic conditions may be treated, improved and/or remedied in accordance with the methods and devices disclosed herein. For example, the disclosed devices and methods may be employed to treat scars, including acne scars, chicken pox scars, hypotrophic scars and the like, for bumps in the skin resulting from scar tissue, for stretch marks, for treating certain parasites (e.g., intradermal parasites such as larva migrans), etc. The disclosed devices and methods may be employed for the removal of tattoos or pigmented lesions, particularly close to the skin surface, where other techniques frequently result in blistering and other skin problems. An improved technique which would permit the fading of such tattoos or pigmented lesions and/or the ultimate removal thereof in a gentle enough manner so as to not cause damage to the patient's skin or significant patient discomfort is also desirable. The devices and methods disclosed herein can be employed to treat vascular lesions including spider veins and other small veins. Where a vascular lesion at a selected depth is being treated, treatment parameters, including the electromagnetic energy source, the optical system, the targeted depth of treatment and the wavelength of the applied radiation are selected so that the at least one depth of the treatment portions are at the depth of the vessel being treated. Similarly, where the treatment is skin remodulation by treatment of collagen or

hair removal, treatment parameters, including the electromagnetic energy source, the optical system, the targeted depth of treatment and the wavelength of the applied radiation are selected so that the at least one depth is the depth of interdermal collagen and the depth of at least one of the bulge and matrix of the hair follicle, respectively. The devices and methods disclosed herein may also be used to treat acne, to target and destroy pockets of fat, to treat cellulite and to treat other skin blemishes, and for treating various other conditions in the skin. The devices and methods disclosed herein can be used not only to remove wrinkles but also to remove other skin blemishes such as acne or chicken pox scars or other scars in the skin. Treatment with the devices and methods disclosed herein can increase the thickness-to-length ratio of the collagen in the area, thus increasing the collagen thickness, resulting in much of the improvement from skin rejuvenation/blemish removal being reasonably permanent. Other skin blemishes treatable by the teachings disclosed herein include stretch marks, which differ from wrinkles in that these marks are substantially flush with the surface, the collagen shrinkage and regeneration as a result of heating reducing these marks. Hypotrophic scarring, the raised scars which occur after surgery or certain wounds, can also be treated by reducing blood flow to the vessels of the scar in much the same way port wine stains may be treated.

In addition to hair removal, treatment of vascular lesions, and skin resurfacing, the teachings disclosed herein may also be used to target and destroy a sebaceous gland or glands, for example to treat acne, to target and destroy pockets of subcutaneous fat, to treat cellulite and to do skin resurfacing on difficult areas, for example neck and hands, where the damage caused using standard skin resurfacing techniques does not normally heal. The treating of only small fractional regions of an overall treatment volume in such areas should leave sufficient undamaged skin structure for healing to occur. The methods and devices disclosed herein can be used to treat various skin cancers, PFB, and psoriasis.

The current approach to managing hair growth and for hair removal is a uniform coverage approach, which leads to energy source(s) requiring high-power and high-power-density. Current energy source requirements can be met with relatively costly professional systems that are designed for and used for professionally treating many customers. For example, one of the most cost effective energy source technologies

employs a diode laser at a near infrared wavelength range suited to treat unwanted hair (e.g., from about 780 nm to about 850 nm). The typical cost of such a diode laser energy source is about \$2/Watt. Since a conventional system requires at least about a 50 Watt source, thus, the energy source alone costs \$100, which is too costly a component part to design a relatively low cost system such as would be suitable for mass production, therefore, designing a low-cost energy source becomes a very difficult task.

Thus, treatment of unwanted facial and body hair with radiation and/or directed energy (e.g., electromagnetic energy in the optical range) has been successfully implemented in a professional setting (e.g., a setting requiring some certification and/or a license to practice the treatment methods). Current teachings universally teach and/or prescribe uniform and/or substantially uniform coverage of the treatment area in order to maximize the treatment effect. Such uniform and/or substantially uniform coverage treatment techniques require a high-power and high-power-density energy source. High-power and high-power-density energy sources carry a relatively high energy source cost. Such high cost energy source(s) are generally limited to a professional setting and make mass production of a method for home use by a consumer costly and thereby difficult to implement.

Developing systems and methods suitable for self-use by a consumer at home is problematic, at least in part, due to costs associated with providing the required energy source. Methods and devices disclosed herein seek to overcome the prohibitive cost limitation(s) and to provide an effective approach to the treatment of unwanted hair with a relatively low-power energy source and with a relatively low cost energy source while also providing a high safety margin. The teachings herein applicable to hair growth management may be applied to acne management, because the techniques can target treatment of follicles including hair follicles (e.g., hair follicles of unwanted hair) and sebaceous follicles related to, for example, acne.

In order lessen the requirement for a high-power and high-power-density energy source; an approach employing non-uniform coverage of the treatment area may be employed. In accordance with the methods and devices disclosed herein, in an embodiment of hair growth management, unwanted hair in a treatment area is treated in a non-uniform manner.

In one embodiment, non-uniform treatment coverage employs two or more treatment sub-areas separated from one another by one or more untreated regions. In one embodiment, the treatment sub-areas are treated with an intensity of electromagnetic radiation. In another embodiment, non-uniform treatment coverage employs two or more treatment sub-areas separated from one another by regions treated at an intensity less than the intensity of the treatment of the one or more sub-areas.

In one embodiment, treatment is electromagnetic radiation and non-uniform treatment coverage can have two or more treatment sub-areas separated from one another by one or more untreated regions or two or more treatment sub-areas separated from one another by regions treated at an with an electromagnetic radiation less than the electromagnetic radiation employed to treat the one or more treated sub-areas.

In one embodiment, treatment is irradiation fluence applied to and/or delivered to the tissue and non-uniform treatment coverage can have two or more treatment sub-areas separated from one another by one or more untreated regions. Alternatively, non-uniform treatment coverage can have two or more treatment sub-areas separated from one another by regions of tissue treated with an irradiation fluence less than the irradiation fluence delivered to the one or more treated sub-areas.

In one embodiment, treatment coverage creates one or more treatment effect occurring in response to application and/or delivery of electromagnetic energy. Treatment effect(s) can include, for example, tissue coagulation – full tissue coagulation or partial tissue coagulation, cell damage, cell modulation, tissue denaturation, or tissue modulation having a hyperthermic effect in response to electromagnetic energy. In one embodiment, non-uniform treatment coverage employs two or more treatment sub-areas separated from one another by one or more untreated regions. In one embodiment, only the treatment sub-areas are treated with electromagnetic radiation. In another embodiment, non-uniform treatment coverage employs two or more treatment sub-areas separated from one another by treated regions where the treatment effect occurring in the treatment sub-areas is greater, larger, and/or more extensive than the treatment effect occurring in the treated regions that separate the treatment sub-areas. For example, in one embodiment, the hyperthermic effect in response to the application of electromagnetic energy is a treatment effect that is greater in the treatment sub-areas than in the treated regions that separate the treatment sub-areas.

By leaving some number of follicles untreated and/or less treated the total power required to accomplish the treatment is less than the power required to treat the area substantially uniformly. In this way, a less costly energy source may be employed relative to the energy source required to do uniform or substantially uniform treatment. Thus, this non-uniform treatment of sub-areas in a treatment area enables use of a lower-cost system such as could be amenable for home use. In addition, the non-uniform treatment approach increases the safety margin of such a treatment as well.

In one aspect, a method of follicle treatment includes selecting a treatment area of skin for follicle treatment, the treatment area includes a plurality of follicles. Contact compression surfaces of two or more point compression elements are pressed into the treatment area. Skin in contact with the contact compression surfaces is displaced by at least about 0.2 mm. In some embodiments, the skin in contact with the contact compression surfaces is displaced by from about 0.2 mm to about 3 mm or from about 1 mm to about 3 mm. Radiation in the wavelength range of from about 400 nm to about 2700 nm, having fluence of from about 1 J/cm^2 to about 200 J/cm^2 , and having a pulse width of from about 1 nanosecond to about 20 seconds is delivered through at least the contact compression surface(s). In some embodiments, radiation is delivered solely through the contact compression surfaces. In other embodiments, radiation is delivered both through the contact compression surfaces of the point compression elements and through the others portions of the applicator outside of the point compression elements.

In one embodiment, the contact compression surfaces have at least one dimension that ranges from about 0.5 mm to about 5 mm or from about 0.5 mm to about 3 mm. For example, in some embodiments, each of the dimensions of the contact compression surface ranges from about 0.5 mm to about 5 mm or from about 0.5 mm to about 3 mm. For example, the area of the contact compression surface can range from about 0.25 mm^2 to about 25 mm^2 , or for example, in a range from about 0.25 mm^2 to about 9 mm^2 . In one embodiment, radiation is delivered in successive pulses with each successive pulse of radiation being delivered through each contact compression surface. For example, radiation is delivered in successive pulses such that a pulse of radiation is delivered to a contact compression surface of a first point compression element and then a pulse of radiation is delivered to a contact compression surface of a second point compression element.

Optionally, the radiation is delivered solely through an inner perimeter of the contact compression surfaces. The radiation may be delivered in successive pulses with each successive pulse of radiation being delivered through the inner perimeter of each contact compression surface.

The plurality of follicles being treated in accordance with the method may be hair follicles, sebaceous follicles or a combination thereof. The depth of the treatment target may be from about 1 mm to about 7 mm or from about 1 mm to about 2 mm for sebaceous gland(s) and/or the hair bulge or from about 2 mm to about 7 mm for the bulb of the hair follicle. In one embodiment, the treatment targets the bulge of a hair follicle and/or the bulb of a hair follicle and the wavelength that is selected is within the range of from about 400 nm to about 1200 nm. In another embodiment, the treatment targets the lipid in the sebaceous gland that surrounds the bulge area of a hair follicle and the wavelength selected is at least one of approximately 924 nm, 1210 nm, and/or 1750. In another embodiment, the treatment target is water in the bulge area and the wavelength that is selected is from about 1200 nm to about 2700 nm. In still another embodiment, the treatment target is the sebaceous gland of a sebaceous follicle and the wavelength that is selected is from about 900 nm to about 2700 nm.

In one aspect, an applicator for creating point compression of tissue includes two or more point compression elements. The two or more point compression elements each have a contact compression surface, each contact compression surface has at least one dimension that ranges from about 0.5 mm to about 5 mm. The applicator is made from a material that is at least partially transparent to an electromagnetic radiation beam having a wavelength range of from about 290 nm to about 11000 nm, having a fluence of from about 0.1 J/cm² to about 1000 J/cm², and having a pulse width of from about 1 nanosecond to 20 seconds. In another embodiment, the applicator is made from a material that is at least partially transparent to a wavelength range of from about 400 nm to about 2700 nm, having a fluence of from about 1 J/cm² to about 200 J/cm², and having a pulse width of from about 1 nanosecond to about 20 seconds.

In some embodiments, the applicator includes a mechanism of attachment to attach the applicator to a treatment device where the treatment device is configured to deliver electromagnetic radiation. Suitable mechanisms of attachment may be, for example, an adhesive, a magnet or a mechanical device. Any of a number of mechanical

- 16 -

devices may be suitable for use to attach the applicator to a treatment device, such as, for example a latch.

5 In some embodiments, the applicator includes an identifier that indicates the compatibility of the applicator with a treatment device. Alternatively or in addition the identifier indicates the presence or absence of the applicator to the treatment device, in this way the treatment device may be enabled to fire only in the presence of the applicator.

10 In one embodiment, solely the contact compression surfaces are partially transparent to the electromagnetic radiation, wherein each contact compression surface has a size larger than the electromagnetic radiation beam delivered therethrough. In this way, the electromagnetic radiation cannot be delivered through the portions of the applicator that surround the contact compression surfaces of the point compression elements.

15 In another aspect, an apparatus for performing a treatment on tissue includes a treatment device configured to deliver successive pulses of electromagnetic radiation. The treatment device has an electromagnetic radiation source. The apparatus also includes an applicator for creating point compression of tissue. The electromagnetic radiation source is in communication with the applicator. The applicator has two or
20 more point compression elements, the two or more point compression elements each has a contact compression surface. Each contact compression surface has at least one dimension that ranges from about 0.5 mm to about 5 mm. The applicator is configured to deliver each successive pulse of electromagnetic radiation through each contact compression surface during operation. In one embodiment, one pulse is delivered
25 through a first contact compression surface and then another pulse is successively delivered through a second (e.g., an adjacent) contact compression surface. In some embodiments, each contact compression surface has a size larger than the electromagnetic radiation beam delivered therethrough.

30 In some embodiments, the applicator includes a mechanism of attachment to attach the applicator to the treatment device. The mechanism of attachment could attach the applicator to the treatment device window or to the body (e.g., the frame) of the treatment device, for example. The mechanism of attachment of the applicator to the treatment device can be, for example, an adhesive, a magnet, or a mechanical device.

- 17 -

Suitable mechanical devices include, for example, a latch, a clip, a clamp, or a tongue and groove arrangement, for example.

5 In one embodiment, the apparatus delivers successive pulses of electromagnetic radiation having a wavelength range of from about 400 nm to about 2700 nm, having a fluence of from about 1 J/cm² to about 200 J/cm², and having a pulse width of from about 1 nanosecond to about 20 seconds.

10 In still another aspect, an apparatus for performing a treatment on tissue includes a treatment device having an electromagnetic radiation source configured to deliver electromagnetic radiation and an applicator for creating point compression of tissue. The electromagnetic radiation source is in communication with the applicator. The applicator has two or more point compression elements and the two or more point compression elements each have a contact compression surface. Each contact compression surface has at least one dimension that ranges from about 0.5 mm to about 15 5 mm. The applicator is configured to deliver electromagnetic radiation therethrough. In one embodiment, the applicator is permanently attached to the treatment device. In another embodiment, the electromagnetic radiation has a wavelength range of from about 400 nm to about 2700 nm, a fluence of from about 1 J/cm² to about 200 J/cm², and a pulse width of from about 1 nanosecond to about 20 seconds. In some embodiments, 20 the electromagnetic radiation is delivered solely through the one or more contact compression surfaces.

DESCRIPTION OF THE FIGURES

25 Figure 1A is front perspective view of a deformation applicator.

Figure 1B shows a point compression element having a trapezoid configuration.

Figure 1C shows a point compression element having a half sphere configuration.

30 Figure 1D shows a point compression element having a rectangle configuration.

Figure 1E shows a point compression element having a parabola configuration.

Figure 1F shows a point compression element having a ball configuration.

Figure 1G shows a point compression element having a cone configuration.

5

Figure 1H shows a point compression element having a cylindrical groove configuration.

10

Figure 1I shows a point compression element having a rectangular groove configuration.

Figure 1J shows a point compression element having a trapezoidal groove configuration.

15

Figure 1K shows a point compression element having an annulus configuration.

Figure 1L shows a point compression element having a pyramid configuration.

20

Figure 2 shows a side view of the deformation applicator shown in Figure 1A.

Figure 3 shows a front Schematic View of the Deformation Applicator of Figure 1A.

25

Figure 4 is a schematic view of treatment using the deformation application of Figure 1A shown before treatment.

Figure 5 is a schematic view of treatment using the deformation application of Figure 1A shown during treatment.

30

Figure 6 is a schematic view of treatment using the deformation application of Figure 1A shown after treatment.

Figure 7 is a front schematic view of another deformation applicator.

Figure 8 is a front perspective view of the deformation applicator of Figure 7.

5 Figure 9 is a schematic view of a deformation applicator in which the pitch is equal to two times the diameter of the point compression element(s).

Figure 10 is a schematic view of a deformation applicator in which the pitch is equal to three times the diameter of the point compression element(s).

10 Figure 11 is a schematic view of a deformation applicator in which the pitch is equal to five times the diameter of the point compression element(s).

Figure 12 is a schematic view of a deformation applicator in which the pitch is equal to seven times the diameter of the point compression element(s).

15 Figure 13 is a schematic view of an experimental deformation applicator in which the pitch is varied across the length of the applicator and the deformation of tissue between adjacent point compression elements changes as the pitch is altered.

20 Figure 14 is a graph showing the results of deformation testes with the Y-axis showing the measured deformation and the X-axis showing the free space between point compression element(s).

25 Figure 15 is a graph comparing the depth of fractional treatment columns with and without 1 mm deformation of tissue and with or without stacking of pulses. The Y-axis shows the depth of the fractional treatment column formed in the tissue and the X-axis shows the number of pulses that were delivered.

30 Figure 16A shows an image of column of damage depth achieved using contact alone and without deformation.

- 20 -

Figure 16B shows an image of column of damage depth achieved using deformation and with the same fiber diameter, mJ, and wavelength conditions as shown in the results of Figure 16A.

5

Figure 17 shows the optical layout when a single fiber acts as a point compression element.

10

Figure 18 shows the optical layout when a single fiber together with an optical prism contacts the skin.

Figure 19A is a parallel polarized image of pig skin tissue treated with the single fiber shown in Figure 17 with the fiber 2 mm above the surface of the pig skin.

15

Figure 19B is a parallel polarized image of pig skin tissue treated with the single fiber shown in Figure 17 with the fiber at the surface of the pig skin.

20

Figure 19C is a parallel polarized image of pig skin tissue treated with the single fiber shown in Figure 17 with the fiber 2 mm below the surface of the pig skin.

Figure 20A shows a computer simulation of skin tissue treated with a fixed surface coverage of 30% and with a 15 mm optic held at the surface of the skin.

25

Figure 20B shows a computer simulation of skin tissue treated with a fixed surface coverage of 30% and with a 10 mm optic held at the surface of the skin.

Figure 20C shows a computer simulation of skin tissue treated with a fixed surface coverage of 30% and with point compression element displacing at least a portion of the skin tissue.

30

Figure 21A depicts treatment of a hair follicle located in skin tissue with a treatment device placed adjacent the skin surface.

- 21 -

Figure 21B depicts treatment of a hair follicle located in skin tissue with a treatment device pressed into the skin surface.

5 Figure 21C depicts treatment of a hair follicle located in skin tissue with a treatment device providing micro-deformation and displacement of skin tissue pressed into the skin surface.

10 Figure 22 shows a plot of the number of treatments on the y-axis and the ratio of Diameter of treatment to Pitch of the point compression elements on the x-axis. The solid line shows the relationship between the number of treatments and the diameter to pitch ratio to achieve 90% total coverage ($CT=0.9$). The dotted line shows the relationship between the number of treatments and the diameter to pitch ratio to achieve 80% total coverage ($CT=0.8$).

15 Figure 23 shows the distribution of light into treated tissue produced with an optic having nine point compression elements where the entire optic is optically transmissive to electromagnetic radiation.

20 Figure 24 shows a treatment device having an applicator with point compression elements treating skin tissue including a hair follicle.

 Figures 25A and 25B depict an applicator having two or more point compression elements being mounted to or disposed on a treatment device handpiece.

25 Figure 25C depicts an applicator having two or more point compression elements in the shape of a rectangle.

30 Figure 25D depicts an applicator having two or more point compression elements in the shape of a rectangle.

Figure 26 shows a treatment device with a flashlamp disposed on an inside surface of a cylinder and two or more point compression elements are disposed about the perimeter of the cylinder.

5

Figure 27A shows a pinched portion of skin tissue having a hair follicle.

Figure 27B shows a pinched portion of skin tissue having a hair follicle and being treated by opposing point compression elements of an applicator.

10

Figure 27C shows a pinched portion of skin tissue having a hair follicle and being treated by offset point compression elements of an applicator.

DETAILED DESCRIPTION

15

Disclosed herein is the discovery that by deforming skin or other tissue in relatively small areas, the electromagnetic radiation ("EMR"), particularly optical radiation such as visible and infrared light, can be delivered to the tissue more effectively. For example, a quantity "A" of EMR can be delivered more deeply into a deformed area of the tissue than if the same area of tissue were not deformed and the quantity "A" of EMR, *e.g.*, the same amount of energy, were delivered. This phenomenon, referred to herein as deformation of tissue (*e.g.*, micro-deformation of tissue), is believed to be particularly applicable to the fractional treatment of tissue with EMR, but also has application in other treatments as well, such as increasing the depth of penetration of non-fractional EMR treatments of tissue.

20

25

The electromagnetic device(s) disclosed herein can have a beam spot size that ranges from about 30 microns to about 3 mm, from about 50 microns to about 1 mm, or from about 50 microns to about 500 microns. The wavelength can range from about 290 nm to about 11000 nm. The pulse width can range from about 1 nanosecond to continuous wave, or from about 1 microsecond to about 100 milliseconds. The fluence can range from about 0.1 J/cm² to about 1000 J/cm². The depth of deformation into the skin (at the deepest point of deformation) can range from about 100 microns to about 3 mm as compared to the normal surface of the skin.

30

Also disclosed is the discovery that deformation of skin tissue (e.g., micro-deformation) provides local deformation using positive or negative pressure to enhance penetration of EMR during the fractional treatment of skin tissue. Without being bound to any single theory, it is believed that skin is compressible, but that tissue fluids (including water, lymph, and/or blood) are not. Since skin comprises 60-70% water, then the compressibility of skin arises in part from the displacement of tissue fluids including water. The deformed tissue accordingly has a modified tissue fluid (e.g., water) content that will change scattering and absorption. In addition to the changes in the optical properties of skin, the thermal properties also may change with compression. For example, with the displacement of tissue fluid (e.g., water), the average, local thermal properties such as thermal conductivity, specific heat, and thermal diffusivity will also change. Local deformation may also be referred to as point compression and/or tissue fluid displacement.

Significant deformation (e.g., micro-deformation) of skin can be achieved in relatively small area (the “deformation area” or “DA”) having a diameter (D). (Note that, although discussed in terms of a circular area having a diameter, many other shapes, configurations and dimensions of a deformed area may be employed. Further, the concepts can be applied also in terms of a small volume or “deformation volume” or DV). Skin may be deformed fractionally, i.e., with a distance between two deformed areas in which there is lesser or no deformation of tissue.

The amount of tissue deformation is significantly greater when accomplished over a number of relatively small areas than when accomplished over a single relatively larger area. The deformation (e.g., micro-deformation) can be performed using a one-dimensional or two-dimensional array or matrix of DAs. Although many configurations are possible, it is thought that the pitch (L) of a matrix of DAs be greater than the diameter (D) of the DAs, i.e., $L/D > 1$. Even more preferably, the array or matrix of DAs has a ratio of L/D that is in the range of approximately 2 to 10. The treatment depth (H) can be increased significantly relative to the deformation depth (h) of the tissue. In other words, the resulting treatment depth (H) can be greater than and/or significantly greater than the deformation depth (h) of the tissue in some embodiments.

In one embodiment shown in Figures. 1A, 2, 3, and 4-6, a deformation applicator 100 includes one or more point compression element(s) 110 (e.g., a set of protrusions extending from the face of the applicator). The point compression element(s) 110 can have any of a number of shapes and/or configurations. Figures 1B-1K show a variety of point compression element 110 configurations. Suitable point compression element(s) 110 can have several shapes and have symmetry about an axis and form a point compression, have symmetry about a plane and form a line compression, and have an annulus to produce a shape of treatment such as a circle, a square (not shown), a rectangle (not shown), a star (not shown), among others, for example. Figures 1B-1K and Table 1 disclose attributes of at least some of the possible point compression element(s) 110 that can be employed in accordance with this disclosure.

Figure	Shape	Symmetry
1B	Trapezoid 110A	About an Axis
1C	Half Sphere 110B	About an Axis
1D	Rectangle 110C	About an Axis
1E	Parabola 110D	About an Axis
1F	Ball 110E	About an Axis or About a Plane
1G	Cone 110F	About an Axis
1H	Cylindrical Groove 110G	About a Plane
1I	Rectangular Groove 110H	About a Plane
1J	Trapezoidal Groove 110I	About a Plane
1K	Annulus 110J	About an Axis
1L	Pyramid 110K	About an Axis
	Waveguide	Light propagates by total internal reflection, this can be an optical fiber

Table 1

15

Referring now to Figures 1A, 2, 3, the applicator 100 has one or more point compression element(s) 110. Referring to Figure 2, the point compression element(s) 110 have a length 112 that ranges from about 0.5 mm to about 10 mm, or from about 1 mm to about 6 mm, or from about 2 mm to about 4 mm. The length 112 is a measure of

the staggered ends and/or protrusions 110 and their length is measured relative to the surface on which they are disposed which enables displacement and/or local deformation of tissue.

5 The distance 111 measured between the center of adjacent point compression element(s) 110 range from about 0.5 mm to about 10 mm, from about 1 mm to about 5 mm, or about 1.56 mm. The portion of the point compression element(s) 110 that contact the tissue surface and compresses the tissue (e.g., the contact compression surface 113) ranges from about 0.001 mm to about 10 cm, from about 0.2 mm to about 5
10 mm, from about 1 mm to about 2 mm, or about 0.54 mm. Depending upon the shape of a given protrusion of the point compression element 110, the contact compression surface 113 may contact a greater portion of the protrusion than is shown in Figure 2. For example, in the point compression element 110B shown in Figure 1C the entire curved portion of the half sphere contacts the tissue. Now referring to Figure 3, in one
15 embodiment, the face of the applicator 110 has an applicator length 114 that ranges from about 2 mm to about 20 cm, from about 5 mm to about 1 cm, from about 10 mm to about 60 mm, or from about 15 mm and has an applicator width 115 that ranges from about 2 mm to about 20 cm, from about 5 mm to about 1 cm, from about 10 mm to about 60 mm, or from about 15 mm. In one embodiment, the face of the applicator 110
20 has a point compression element array length that ranges from about 0.5 mm to about 18 cm, from about 3 mm to about 1 cm, from about 8 mm to about 50 mm, or from about 10.42 mm and has a point compression element array width that ranges from about 0.5 mm to about 18 cm, from about 3 mm to about 1 cm, from about 8 mm to about 50 mm, or from about 10.40 mm.

25 Referring to Figures 4-6, the point compression elements 110 are configured to contact the tissue 200 skin 210 during an EMR treatment. In one embodiment, all or a portion of the applicator 100 is made from an optically transmissive substance, such as sapphire. In another embodiment, all or a portion of the point compression element(s) 110 are made from an optically transmissive substance, such as sapphire. Other
30 suitable optically transmissive substances and/or materials that may be employed to make all or a portion of the applicator 100 and the point compression element(s) 100 include dielectrics, ceramics, diamond, quartz, polymers, glass, Lucite, and crystals, for example. In one embodiment, point compression element(s) 100 are at least partially

transparent to enable EMR (e.g., optical radiation) to travel therethrough. In one embodiment, one or more point compression element(s) are have a hole and/or plug made of transparent material such as sapphire that enables EMR to travel through the point compression element(s), optionally, portions that surround by transparent material are non transparent (e.g., made from metal(s) or polymers(s), etc.)

[001] Referring now to Figures 4-6, the point compression elements 110 (e.g., the protrusions for an array of deformation applicators with size (D) and pitch (L)) can be coextensive with and/or correspond to a matrix of fractional beams. Figure 5 shows fractional beams 300 that are coextensive with the point compression elements 110. In one embodiment, a matrix of fractional beams 300 each has a diameter (d) that is less than (D) and a pitch (l) that is equal to (L). In one embodiment, the applicator is configured to be attached to a suitable EMR treatment device such as a fractional treatment device or other device.

Referring to Figures 4-6, the deformation applicator 100 is positioned over the skin surface 210 of a region of tissue 200. In Figure 5, one or more point compression element(s) 110 are pressed into the skin surface 210 (e.g., the epidermis). A portion of the skin surface 210 is compressed and/or deformed under the point compression element 110. In the space between adjacent point compression element(s) 110 the skin surface 210 is not compressed and/or is not compressed in the manner that the skin surface 210 is compressed under the point compression element(s) 110. At least some tissue fluid (e.g., water, blood, lymph etc.) is displaced by the point compression element(s) 110. In one embodiment, the amount of tissue fluid displacement varies as a function of the length of time that the applicator 100 and its point compression element(s) 110 are pressed onto the surface of the skin 210. The longer the point compression element(s) are pressed onto the surface of the skin 210 prior to treatment with EMR the greater the opportunity for tissue fluid displacement. In one embodiment, the point compression element(s) are pressed onto the surface of the skin 210 for a time that ranges from about 0.5 seconds to about 10 minutes, from about 1 second to about 1 minute, from about 2 seconds to about 10 seconds, or for a length of time determined suited to the particular desired outcome by the practitioner performing the procedure. The external skin surface 210 may retain the imprint of the point compression element(s) 110 for a period of time after they are pressed onto the surface of the skin 210 until, for

- 27 -

example, the tissue fluid returns to the regions of deformation to reduce and/or remove the appearance of the imprint on the skin surface 210.

Fractional beams 300 are delivered into the skin surface 210 and into the tissue 200 such that one fractional beam travels through a single point compression element 110 and into the compressed tissue in contact with the point compression element 110. Treatment zone(s) of damaged and/or treated tissue 310 are created in the tissue 200. The zones of treated tissue 310 are deeper than would have been achieved if the same fractional beams 300 (e.g., the same EMR) were provided in the absence of compression of the tissue 200 with the point compression element(s) 110. More specifically, tissue fluid displacement occurs where the point compression element(s) are pressed onto the surface of the skin 210. There may be some tissue fluid displacement in the regions of tissue 200 between adjacent point compression element(s) 110, however, the amount of tissue fluid displacement in the tissue 200 compressed by the point compression element(s) 110 is greater than and/or significantly greater than any displacement in the regions of tissue 200 between adjacent point compression element(s) 110.

These changes in compressed tissue may combine to enhance desired thermal effects arising from photothermolysis. For example, the adiabatic application of radiation to heat tissue to a desired temperature (e.g., for coagulation) will become possible at lower laser power levels where there is a decrease in thermal diffusivity of the tissue (with all other parameters the same). The adiabatic application of radiation means that the heat is delivered to the tissue at a faster rate than the rate at which the object (e.g., the treated tissue) will cool. In particular, the adiabatic condition is characterized by the thermal relaxation time, τ_R , which is inversely proportional to the thermal diffusivity

$$\tau_R \propto \frac{D^2}{\alpha}$$

(Formula 1)

30

- 28 -

Here D is a length characteristic of the geometry of the EMR beam and α is the thermal diffusivity that depends on the following thermal properties of the tissue:

$$\alpha \propto \frac{\kappa}{\rho C_p}$$

5

(Formula 2)

κ is the thermal conductivity of the tissue, ρ is the density of the tissue and C_p is the specific heat of the tissue. If the tissue thermal diffusivity decreases as water concentration decreases, then the relaxation time increases and the achievable temperature rise also increases for a given incident EMR power. As a result, where a decrease in diffusivity results from a decrease in tissue fluid (e.g., water) concentration due to deformation (e.g., micro-deformation) and/or point compression, one can reduce the input power required to achieve a desired temperature rise. It is believed that the level of deformation (e.g., micro-deformation) and/or point compression can be optimized to achieve the desired diffusivity properties. The time of tissue deformation and/or point compression prior to applying EMR can be selected and/or altered to allow tissue fluid (e.g., water and/or collagen) concentration to decrease. Generally, applying a point compression element for a longer period of time enables a greater quantity of tissue fluid to displace thereby further reducing tissue diffusivity and providing the benefits associated therewith.

The thermal capacity of the tissue is altered (e.g., decreased) by employing local deformation, also referred to as point compression, which results in tissue fluid displacement. This allows for enhanced cooling of the deeper tissues, because there is better thermal contact between the point compression element(s) and the surface of the subject's skin (e.g., the stratum corneum of the subject's skin). In addition, cooling of deeper tissues is also enhanced by decreasing the tissue fluid content, because employing one or more point compression element(s) on the surface of a tissue lowers the heat capacity of the tissue in contact with the point compression element, e.g., the portion of the skin surface in contact with a point compression element having a pin-like shape (see, e.g., Figures 1B and 1G). In addition to decreased absorption of the light by skin (e.g., the water in skin tissue) the reduction in heat capacity enhances cooling to

better preserve the D/E junction. Further, all or a portion of the deformation element may be cooled. In one embodiment, only the point compression element(s) are cooled. In another embodiment, only a portion of the point compression element(s) are cooled (e.g., only the distal end of the point compression element(s) in contact with the skin surface are cooled). For example, the point compression element optic may be cooled by any of a number of means (e.g., gas, liquid (water, refrigerant, or any coolant), thermoelectric, vaporization, and/or melting). Optionally, the point compression element is actively cooled and a regulated flow of coolant is provided to the point compression element optic to ensure a substantially consistent temperature. Employing cooling enables higher energy to be delivered to the skin tissue by controlling and/or limiting damage to the surface of the skin tissue (i.e., down to and including the dermal-epidermal junction (i.e., the D/E junction). In this way adverse events such as hyper-pigmentation and/or hypo-pigmentation may be minimized and/or avoided.

Also, a decrease in tissue fluid (e.g., water) content caused by tissue compression and/or deformation (e.g., micro-deformation) may cause a decrease in the tissue's scattering and absorption properties such that light can penetrate more deeply into the tissue compared to a treatment using the same energy and other parameters but lacking deformation (e.g., micro-deformation) of the tissue with the point compression element. In cases where the tissue is compressed, the deformed tissue has a smaller volume and, following mechanical relaxation, the treated tissue extends to a larger volume. In cases where the tissue is extended, the opposite is true, i.e., the deformed tissue has a larger volume and, following mechanical relaxation, the treated tissue extends to a smaller volume.

In addition to allowing for deeper penetration of light and deepening of the treatment zone, by employing a point compression element the area of "damage" or "treatment" induced by the EMR may be reduced at the superficial layers of the skin, e.g., at the epidermis. Superficial skin layer damage may be reduced and/or avoided because better contact with the skin provides better heat transfer from the skin and/or the subcutaneous tissue (e.g., fat tissue) to the contacting optic. Superficial skin layer damage may be reduced and/or avoided because a decrease in local tissue fluid concentration and the resulting decrease in tissue scattering will lower the energy deposited in the upper layer to decrease the amount of thermal damage. Thus

- 30 -

employing a point compression element and to achieve local deformation enables one to increase the volume of tissue treated without increasing damage at the dermal-epidermal junction. Reducing the damage at the dermal-epidermal junction can decrease the risk of, for example, hypo-pigmentation and hyper-pigmentation. In addition, employing a point compression element to achieve local deformation enables the a tissue volume to be treated with a relatively lower power device than would be required in the absence of location deformation provided by, for example, a point compression element.

Referring again to Figures 4-6, during treatment, the applicator 100 is pressed into the surface 210 of an area of tissue 200, in this case skin. The one or more point compression element(s) 110 (e.g., protrusions) on the applicator 200 press onto the surface 210 of the skin and, in one embodiment, do not pierce and/or cut into the skin surface 210. The tissue is thereby deformed by the one or more point compression element(s) 110 pressed into the skin surface 210. While deformed, an array of beams 300 of EMR, each having a diameter (d) and a pitch (l), is applied to the tissue. The array of EMR beams 300 creates an array of treatment zones 310 each having a treatment depth (h). The applicator 100 is then removed from the tissue 200, and the tissue relaxes resulting in a treatment depth (H) for each treatment zone 310. In one embodiment, the diameter (d) of each beam is less than the size (D) of the point compression element (e.g., the protrusion) through which the beam 300 is applied to the surface 210 of the tissue 200. Another embodiment of the applicator 100 is shown in Figure. 7 through 8. The applicator 100 shown in Figure 7 is similar to the applicator in FIG. 1, but has a circular configuration, which is different from the square configuration shown in Figure 1. The face of the applicator 100 that contacts the skin surface during use for treatment of tissue is circular and each point compression element 110 (e.g., each protrusion on the applicator 100), which collectively form the array of DAs, have a pointed pyramid-like shape similar to the shape depicted in Figure 1K.

Many other embodiments of the device and method discussed in connection with Figures 1A-1L are possible. For example, the tissue (e.g., the skin) can be expanded rather than compressed. The point compression elements (e.g., the protrusions) can be shaped and sized differently, including, without limitation, longer, shorter, narrower, wider, rounded, pointed, squared cross sectional areas, and the cross sectional areas and shapes disclosed in connection with Figures 1A-1L, for example. In one embodiment, a

- 31 -

single applicator can have a point compression elements having varying sizes (e.g., length, width) and varying shapes (e.g., a pyramid and a groove). The point compression elements (e.g., protrusions) can be elongated lines or ridges, pin-points, circular, oval, rectangular, or square in shape, or can have many other shapes. Further, a single array can include regularly spaced and uniformly shaped protrusions or the dimensions of the array and/or the protrusions in the array can be varied to many other configurations. Additional forms of deformation or a combination of forms of deformation can be used. For example, vacuum pressure applied at the perimeter of an applicator (e.g., in the region of the applicator length 114 and the applicator width 115 as depicted in Figure 3) can be used to stretch the tissue over the applicator as the skin is deformed with the protrusions of the applicator. In various embodiments, different fractional treatment devices can be used, for example, a device having an array of micro-lenses can be used (e.g., can be used in a "stamping mode") as well as a device that includes a scanner, e.g., that can be used in a scanning mode. Additionally, other embodiments can be employed with non-fractional EMR-based devices, as well as devices (fractional and non-fractional) that use other types of energy, including, without limitation, optical, ultrasound, microwave, and RF energy sources. The applicator can be formed as a permanent attachment incorporated into a treatment device or can be detachable, e.g., as part of a set of applicators for various purposes and/or as a disposable applicator.

The applicator 100 can be reversibly attachable and/or disposable. In one embodiment, the applicator is an optic that reversibly attaches to a treatment device. The applicator can attach to, for example, the treatment device window and/or to the body of the treatment device (e.g., the outer frame of the treatment device). Any of a number of suitable mechanisms of applicator attachment may be employed. For example, the applicator (e.g., the side of the applicator that does not feature the point compression elements) may be attached to the treatment device by an adhesive, by a magnet, by a mechanical device or method such as a latch, a clip, a clamp, a complementary fit such as tension fit, tongue and groove etc.

In one embodiment, the applicator 100 has an identifier that indicates the compatibility of the applicator with a treatment device. Optionally, the identifier can indicate that the applicator 100 is suitable for use with the treatment device. The

identifier can enable the applicator to be used only with certain compatible treatment devices and can prevent the use of the incompatible applicators with the treatment device. This way, the identifier can ensure the only applicators made by allowed applicator manufacturers are used with the treatment device. This way, counterfeiting of applicators can be avoided and/or quality of the applicator can be controlled.

Alternatively, or in addition, the identifier can indicate the presence of the applicator 100 to the treatment device and/or the proper attachment of the applicator to the treatment device. Where the identifier indicates the presence and/or proper attachment of the applicator to the treatment device the indication by the identifier of the presence and/or proper attachment of the applicator can enable the treatment device to be used.

The identifier can be a tag, for example, an electronic chip such as an RFID tag that indicates that an applicator is suitable for use with the treatment device. The identifier can be, for example, a specific shape, structure, thickness or other physical characteristic that enables the applicator to be used only with certain compatible treatment devices. At least a portion of the treatment device and/or the applicator can have a physical characteristic that enables only certain complementary treatment device(s) and/or applicator(s) to be used with it. The identifier (e.g., the tag and/or the physical characteristic(s)) can prevent the use of the applicator with incompatible treatment devices.

The applicator is at least partially transparent to the energy being applied through the applicator. In one embodiment, the applicator is at least partially transparent to an electromagnetic radiation beam having a wavelength range of from about 290 nm to about 11000 nm, having a fluence of from about 0.1 J/cm^2 to about 1000 J/cm^2 , and having a pulse width of from about 1 nanosecond to continuous wave or having a pulse width of from about 1 nanosecond to 20 seconds. In another embodiment, the applicator is at least partially transparent to a wavelength range of from about 400 nm to about 2700 nm, having a fluence of from about 1 J/cm^2 to about 200 J/cm^2 , and a pulse width of from about 1 nanosecond to continuous wave or having a pulse width of from about 1 nanosecond to 20 seconds.

In one embodiment, only the contact compression surfaces of the point compression elements are transparent to the electromagnetic radiation beam. In another embodiment, the whole applicator is transparent to the electromagnetic radiation beam such that portions of the applicator that surround the point compression elements are transparent to the electromagnetic radiation and the point compression elements are also transparent to the electromagnetic radiation beam.

Experimental Tests of Various Micro-Deformation Applicators

Devices similar to the embodiment described in conjunction with FIG. 1A were tested in an in vitro study. The applicator embodiments used and the results of the study are described in conjunction with the following figures. As shown in the schematic diagrams of Figures 9-12 a set of 500 micrometer fibers were used. Figure 9 shows a set of 500 micrometer fibers that each have a circular cross section in which the pitch (L) is two times the diameter (D) of the fibers. The point compression element(s) 110 are staggered with ends displaced approximately 1 mm from the ends of adjacent fibers to provide local deformation of tissue.

Figure 10 shows a set of 500 micrometer fibers that each have a circular cross section in which the pitch (L) is three times the diameter (D) of the fibers. The point compression element(s) 110 are staggered with ends displaced approximately 1 mm from the ends of adjacent fibers to provide local deformation of tissue.

Figure 11 shows a set of 500 micrometer fibers that each have a circular cross section in which the pitch (L) is five times the diameter (D) of the fibers. The point compression element(s) 110 are staggered with ends displaced approximately 1 mm from the ends of adjacent fibers to provide local deformation of tissue.

Figure 12 shows a set of 500 micrometer fibers that each have a circular cross section in which the pitch (L) is seven times the diameter (D) of the fibers. The point compression element(s) 110 are staggered with ends displaced approximately 1 mm from the ends of adjacent fibers to provide local deformation of tissue.

A test employing the applicators shown in the schematic diagrams of Figures 9-12 evaluated the effect of varying the distance between the fibers configured to deform tissue (see, e.g., dx - var on Figures 9-12), this spaces is also referred to as the free space (see, e.g., Figure 14).

Referring to Figures 9-13, the distances between the extended fibers (e.g., the point compression element(s) 110) were varied to examine the effect of the various dimensions on the tissue (i.e., pig skin). As shown in FIG. 13, the deformation of tissue between adjacent extended fibers increased as the pitch of the extended fibers increased (i.e., as the distance between the fibers configured to deform tissue is increased and as the free space between adjacent point compression elements is increased). The applicator 100 is compressed into the pig skin. Generally, a relatively small amount of deformation (Δ) occurred when the pitch (L) was approximately equal to the diameter (D) of the fibers, while the tissue deformation increased as the pitch (L) increased. More specifically, referring to Figure 14, where the free space A was approximately equal to the diameter of the point compression element 110, the deformation in the free space A ($\Delta_{FS(A)}$) is very small.

Where the free space B was approximately equal to two times the diameter of the point compression element 110, the deformation in the free space B ($\Delta_{FS(B)}$) is still small, but is larger than the deformation in the free space A ($\Delta_{FS(A)}$). Where the free space C was approximately equal to three times the diameter of the point compression element 110, the deformation in the free space C ($\Delta_{FS(C)}$) is larger than the deformation in the free space B ($\Delta_{FS(B)}$) and is larger than the deformation in the free space A ($\Delta_{FS(A)}$). Where the free space D was approximately equal to four times the diameter of the point compression element 110, the deformation in the free space D ($\Delta_{FS(D)}$) is larger than the deformation in the free space C ($\Delta_{FS(C)}$), is larger than the deformation in the free space B ($\Delta_{FS(B)}$), and is larger than the deformation in the free space A ($\Delta_{FS(A)}$). There the deformation in the free space is relatively larger e.g., the deformation of the free space D ($\Delta_{FS(D)}$) pig skin tissue contacts the contact compression surface of the point compression element(s) 110 that surround the free space D, but in addition at least a portion of the tissue between adjacent point compression element(s) 110 contact the applicator (e.g., shorter fibers between the adjacent point compression elements) in the region of the free space D. In addition, referring still to Figure 13, the region of greatest deformation by the point compression element(s) 110 is where the length of the point compression element 110 (i.e., Δ_p) is substantially the same as the deformation of the free space D ($\Delta_{FS(D)}$).

Referring to the graph in FIG. 14, the results of deformation testing of pig skin described in relation to Figures 9-13 are shown. The Y-axis shows the measured deformation (Δ , mm) of the tissue in the direction of the depth of the skin tissue (approximately normal to the skin surface). The X-axis marked free space between fiber has the following relationship with the pitch (L), at 0.5 mm, $L = 2D$; at 1.0 mm, $L = 3D$; at 2.0 mm, $L = 5D$; at 3.0 mm, $L = 7D$; and at 3.5 mm, $L = 8D$. The measured deformation increased as the free space between the adjacent point compression elements (e.g., protrusions and/or extended fibers) increased. The graph at FIG. 14 shows that the increase in the measured deformation of the tissue has a substantially linear relationship with the increase in free space between adjacent point compression elements (e.g., protrusions and/or extended fibers).

Following the deformation tests, tests were conducted to compare the results of fractional columns created by irradiating pig skin tissue using a set of fibers placed in contact with the surface of the pig skin tissue (and without deformation) and fractional columns created using the same device, but with the device further pressed into the tissue to create various magnitudes of deformation (e.g., micro-deformation) using point compression elements in a direction roughly normal to the upper surface of the pig skin tissue. A summary of the results of the tests are shown in the graph shown in Figure 15. In Figure 15 the X-axis shows the number of pulses that were delivered and the Y-axis shows the depth of the fractional treatment column formed in the tissue as a result of the EMR delivered via the varying pulses. During each of the tests summarized in Figure 15, the applied wavelength was 1540 nm, using 200 mJ, at a fluence of 125 j/cm^2 , at a pulse width of 13.5 ms and at 0.2 Hz the number of pulses varied during the testing such that one test included $N=1$ pulse, another test included $N=5$ pulses, and another test included $N=10$ pulses. Figure 15 shows that employing point compression element(s) at a deformation depth of 1 mm in tissue together with fractional EMR directed through each point compression element when located at 1 mm depth in tissue enables formation of a column deeper in tissue than is possible with fractional EMR in the absence of deformation. In addition, use of 1 mm of deformation enables column formation in a single pulse at a depth that is deeper than is available with ten "stacked" pulses (e.g., ten pulses of fractional EMR in the same location in a single islet of damage) in the absence of and with no deformation.

Figure 16A shows an image of column depth achieved using contact alone (without deformation) and applying 1540 nm at 200 mJ via a 400 μ m fiber. Figure 16B shows an image of column depth achieved using 1 mm deformation and applying 1540 nm at 200 mJ via a 400 μ m fiber. Comparing applying deformation (see, Figure 16B) enables formation of column depths that are much deeper than with contact alone and in the absence of deformation (see, Figure 16A).

Deformation applicators (e.g., micro deformation applicators including one or more point compression element(s)) were also tested on ex vivo porcine skin and in human skin. Figures 17-18 depict the optical layouts where a single pin in the form of a 0.6 mm diameter fiber acts as a point compression element. The 0.6 mm diameter fiber is disposed in a ferrule, a tube that surrounds all or a portion of the 0.6 mm diameter fiber, the outside diameter of the ferrule enclosing the 0.6 mm fiber is 1.8 mm. Laser emission from a diode bar 400 at 1208 nm is coupled into a 600 micron diameter fiber, which acts as a point compression element 110. Figure 17 shows a system where the 600 micron fiber 110 is applied directly to the skin surface 210 and compression is applied by the 600 micron fiber, which acts as a point compression element 110 to deform the skin 210 by a specified amount that ranges from 0 mm to 5 mm. Figure 18 shows a system where the output light from the 600 micron fiber is applied to the skin surface 210 through an intermediate window 420, a sapphire pyramid optic. This sapphire pyramid optic 420 is then applied to the skin surface 210 and the skin is compressed below the pyramid optic 420. The portion of the pyramid optic 420 that contacts the skin surface 210 measures 2 mm and the end of the bare fiber that acts as the optical compression element 110 is about 2 mm from the surface of the skin 210. The setup shown in Figure 18 may be used with or without a lens for focusing the micro beam.

The results demonstrate an increase in the depth of the coagulation zones with compression. Figures 19A-19C provides parallel-polarized images of pig skin tissue treated with the single bare fiber in Figure 17, the treated tissue and/or damaged tissue 310 becomes quasi transparent. The single bare fiber shown in Figure 17 has no adjacent fibers to share the tensile load of the skin. Figures 19A-19C show the parallel-polarized images of 150 micron thick pig skin after treatment with 2.5 Watts of laser radiation for 10 seconds. Figure 19A shows the results where the fiber is 2 mm above the surface of the pig skin these results are achieved with the device of Figure 17 is

- 37 -

positioned 2 mm above the surface of the pig skin. Figure 19B shows the results where the fiber is at the surface of the pig skin, these results are achieved with the device of Figure 17 where the end of the point compression element is placed at the surface of the pig skin, but is not pressed into to deform the pig skin. Figure 19 C shows the results where the fiber is pushed about 2 mm below the surface of the pig skin; these results are achieved with the device of Figure 17 where the end of the point compression element 110 is pushed into the surface of the pig skin to deform the pig skin. The results in Figures 19A-19C demonstrate an increased depth of coagulation with compression.

Increased compression caused by deforming the skin to 2mm (Figure 19C) increases coagulation depths by 20% as compared to the results shown in Figure 19B where the fiber was not compressed into the skin, but was at the surface of the skin. Generally, the deeper the pin is pressed into the skin surface, the deeper the depth of damage into the tissue.

In addition, referring still to Figures 19A-19C, the diameter of damage at the surface of the compressed skin is less than the damage at the surface of the skin where the skin is not compressed. For example, the compressed tissue damage at the skin surface is 22% narrower in diameter than the non compressed skin. Avoiding and/or lessening damage at the skin surface can lessen the likelihood of adverse events such as hypo-pigmentation and/or hyper-pigmentation. Further, in some embodiments, dermal-epidermal separation can be reduced by employing local deformation (e.g., point compression element(s) to the skin surface).

In one embodiment, a fractional treatment at a wavelength of 1440 nm at 70 mJ was performed with and without location deformation employing one or more point compression element(s). As a result of the local deformation, the dermal-epidermal separation was reduced by from about 15% to about 30% and the depth was increased from about 20% to about 50% relative to the fractional treatment performed without local deformation, e.g., without compression applied by point compression element(s) to the skin surface. Avoiding and/or lessening the dermal-epidermal damage is important to avoid and/or lessen adverse events including hyper-pigmentation and hypo-pigmentation.

In one embodiment, employing the devices and methods to deform tissue using the one or more point compression element(s) enables the permeability of the stratum cornea and/or the epidermis to be controlled. More specifically, the deformation of the tissue achieved using the one or more optical compression element(s) stretches the stratum cornea in a manner that is remarkable and/or dramatic as compared with deformation provided using an apparatus that covers a larger area than the point compression elements such that there is not much deformation in the free space between point compression element(s).

In one embodiment, a compound is delivered to the surface of the skin (e.g., the epidermis) prior to treatment with the device(s) and/or the method(s) employing one or more point compression element(s) disclosed herein. Alternatively or in addition, suitable compounds can be delivered through the stratum cornea, into the stratum cornea, through the epidermis, into the epidermis, through the dermis, or into the dermis in accordance with the device(s) and/or the method(s) employing one or more point compression element(s) disclosed herein. Suitable compounds can enhance the benefits available from light treatment (e.g., a collagen promotion compound such as vitamin A or vitamin C may be employed). Others suitable compounds can enhance healing from light treatment, for example, anti inflammatory compounds may be employed to potentially decrease the side effects of treatment (e.g., antihistamine to decrease erythema). Other suitable compounds can have a refractive index that is close to or matches the refractive index of the area that is targeted by the light (e.g., interstitial fluids in the tissue, collagen, and other proteins).

In another embodiment, chromophores such as dyes, organic dyes, or carbon particles are delivered through the stratum cornea, into the stratum cornea, through the epidermis, into the epidermis, through the dermis, or into the dermis in accordance with the device(s) and/or method(s) employing one or more point compression element(s) disclosed herein. In one embodiment, after delivery of the chromophore to the desired location, light (e.g., light targeting the chromophores) is selected to destroy the tissue in which the chromophores are resident (e.g., the stratum cornea, the epidermis, and/or the dermis). In one embodiment, light treatment of the chromophores cause a sufficient localized temperature rise to alter the permeability characteristic of skin (e.g., SC) can be effected.

Referring now to Figures 20A-20C, it is possible to increase the volume of treatment while maintaining a fixed coverage surface. In this way, the risk of adverse events associated with excess treatment of the dermal-epidermal junction can be lessened and/or avoided while achieving a greater treatment volume. Figures 20A-20C shows a computer simulation of skin tissue treated with a fixed surface coverage of 30%, such that in a given region of skin only 30% of the surface of the skin is treated. The computer simulation depicted in Figures 20A-20C is in good agreement with treatment column profiles (e.g., of coagulated columns) seen experimentally.

Figure 20A shows a 15 mm optic provided at a wavelength of 1440 nm and at 8 mJ, which achieves a depth of 320 microns and a maximum diameter of 150 microns, the distance between adjacent 15 mm optics is about 0.6 mm with coverage of 30% at the surface of the skin tissue. Figures 20B shows a 10 mm optic provided at a wavelength of 1440 nm and at 70 mJ, which achieves a depth of 600 microns and a maximum diameter of 400 microns the distance between adjacent 10 mm optics is about 1 mm with coverage of 30% at the surface of the skin tissue. Finally, Figure 20C shows one or more point compression array element(s) provided at a wavelength of 1440 nm and at 70 mJ, which achieves a depth of 860 microns and has a maximum diameter of 400 microns with coverage of 30% at the surface of the skin tissue. The diameter of each fraction of treated tissue at the skin surface is less in Figure 20C than in Figure 20B, despite that both treatment models use a 1440 wavelength at 70 mJ. This difference appears to be due to use of the point compression element(s) applying pressure to the tissue and the resulting tissue fluid displacement, which lessens damage at the dermal-epidermal compared with a treatment at the surface of the skin and in the absence of use of point compression element(s). Because the damage at the dermal-epidermal junction is lessened, the related risks of hyper-pigmentation and hypo-pigmentation associated with excess damage, e.g., from about 30% to about 95% damage, of from about 35% to about 65%, or about 50% damage at the surface of the skin, is also reduced. The volume of treatment in the point compression element model to displace tissue and depicted in Figure 20C is two times the volume of treatment in the model depicted in Figure 20B that is at the surface of the skin tissue and does not apply displace the tissue. Further, other than the use of displacement by the point compression element(s) and treatment at the surface of the skin, the models at Figures 20B and 20C

- 40 -

use all of the same conditions (e.g., 1440 nm, 70 mJ). Finally, the volume of treatment in the point compression element model to displace tissue and depicted in Figure 20C is four times the volume of treatment in the model depicted in Figure 20C that is at the surface of the skin tissue and does not apply displace the tissue. The cross sectional profile of the treated tissue modeled in Figure 20C can be described as a teardrop, whereas the cross sectional profile of the treated tissue modeled in Figures 20A and 20C can be described as a column.

In some embodiments, a deformation applicator including point compression element(s) is employed together with stacking the pulses to thereby enhance penetration of the tissue treatment region. Where a stacked pulse strategy is employed, the point compression element(s) are compressed into the tissue surface and without moving the applicator EMR is applied to the tissue surface repetitively at some fixed interval. When using stacked pulses, the EMR can be applied by, for example, firing a laser, repetitively in a single treatment zone or within a single array of treatment zones without moving the applicator. EMR can be applied from about 2 times to about 20 times or from about 2 times to about 5 times. Where point compression element(s) are employed with a stacked pulse strategy the impact of maintaining the point compression element in a single location without movement can be to enhance displacement of tissue fluid to thereby improve scattering and absorption and improve the depth of coagulation due to the stacked pulses.

Combination Fractional Ablative and Fractional Non-Ablative

Fractional non-ablative techniques result in coagulation of tissue and other forms of thermal injury, e.g. cell death, cell apoptosis and/or heat shock and/or protein generation. Coagulation and related thermal injury are important factors in skin rejuvenation, but they are limiting factors for maximizing single treatment coverage of fractional non-ablative deep treatments. More specifically, the amount of coverage in a fractional non-ablative treatment is limited by the risk of long term side effects (e.g., hyper pigmentation). Coverage may refer to the area of damage (relative to the total treatment area). More specifically, damage is created in a volume of tissue and the shape of this volume can be a column. This column of damage may assume the shape of e.g., a cylinder, tear drop, arrow, dagger or wedge or any other geometric shape with

symmetry. Slicing a plane through these volumes of treated tissue whereby the plane is parallel to the skin surface enables quantification of the coverage in that plane. The coverage in this plane is defined as the total area of damage divided by the total area.

5 Coverage at planes of different depths can vary. For example, if the column of damage has a cylindrical shape, the coverage is substantially the same at different depths. If the column of damage is of a tear drop shape, then the coverage will increase with depth from the skin surface, go through a maximum and then decrease with increasing depth. For example, where non-ablative treatment such as Lux1540 are employed, the collagen
10 denaturation profile may be non-cylindrical and therefore the coverage at a given depth below the dermal-epidermal junction (the D/E junction can) be greater and/or less than the coverage at the D/E junction. In these instances, one can define coverage either to be the coverage at the D/E junction or the coverage at the depth (e.g., one of several depths in the tear drop shape damage profile) causing maximum coverage (i.e., that has the
15 largest area at a given depth).

Generally non-ablative fractional treatment involves a treatment coverage area that is close to but does not reach the quantity of coverage that is known to cause long term side effects (e.g., hyper pigmentation) this is referred to as the maximum coverage for the fractional non-ablative treatment modality. As a result, multiple non-ablative
20 treatments (e.g., three to four treatments) each separated by healing time are generally required to treat a condition (e.g., dyschromia). Generally, the maximum coverage for a single fractional non-ablative treatment is about 30% (e.g., treats the fraction of the tissue exposed to the device and the fraction is 30%), or from about 20% to about 40%.

Likewise, the amount of coverage in a fractional ablative treatment is limited by
25 the risk of long term side effects (e.g., hyper pigmentation) and the risk of extensive downtime. Generally, ablative fractional treatment involves a single treatment. Generally, the maximum coverage for a single fractional ablative treatment modality is from about 30% to about 40%. Depending on the depth of treatment and the percentage coverage employed (the coverage ranges from about 10% to about 40%) the amount of
30 downtime associated with a fractional ablative procedure ranges from about 2 days to 7 days.

- 42 -

The non-ablative treatments include a wavelength range of from about 900 nm to about 2600 nm. The ablative treatments include a wavelength range of from about 2600 to about 11000 nm. In one embodiment, the non-ablative treatment occurs prior to the ablative treatment. In another embodiment, the ablative treatment is conducted prior to the non-ablative treatment. In accordance with the methods disclosed herein, two separate electromagnetic radiation devices, one non-ablative and the other ablative, are employed to conduct the combination non-ablative and ablative treatment in a single session. In another embodiment, a single electromagnetic radiation device features two sources, one ablative and the other non ablative.

In still another embodiment, a single electromagnetic radiation device emits a wavelength range in the non-ablative range, i.e., from about 900 nm to about 2600 nm. The laser is enhanced by employing a coherent pump laser that converts the non ablative electromagnetic radiation device to make it ablative such that it emits a wavelength range in the ablative range, i.e., from about 2600 nm to about 11000 nm. A coherent pump laser is simply one exemplary converter that can convert a non-ablative electromagnetic radiation device to operate as an ablative device; any other suitable converters are contemplated herein and may be employed. The electromagnetic device disclosed herein can have a beam spot size that ranges from about 30 microns to about 3 mm, from about 50 microns to about 1 mm, or from about 50 microns to about 500 microns. The pulse width can range from about 1 nanosecond to continuous wave, or from about 1 microsecond to about 100 milliseconds. The fluence can range from about 0.1 J/cm² to about 1000 J/cm².

In one embodiment, the coagulate damage caused by non-ablative fractional treatment is combined with the ablative damage caused by fractional ablative treatment. The combination of non-ablative fractional and ablative fractional offers an opportunity to vary systematically both treatment modalities. The combination of fractional ablative and fractional non-ablative treatments can be employed in a single patient treatment/patient visit to improve cosmetic conditions including, but not limited to: wrinkles, skin tightening, discromia, vascular lesions, pigmented lesions, acne, acne scars, surgical scars, atrophic scars, and stretch marks.

In one embodiment, in a single patient treatment and/or a single patient visit to the practitioner, a non-ablative fractional treatment is combined with an ablative fractional treatment. In one embodiment, the fractional non-ablative portion of the treatment is performed prior to the fractional ablative portion of the treatment. In
5 another embodiment, the fractional ablative treatment is performed prior the fractional non-ablative treatment. The fractional non-ablative treatment can coagulate the treated tissue from the surface down to deep portions of the skin, for example, as deep as the dermal hypodermal junction. The fractional ablative treatment can create voids in the
10 treated tissue such that the voids are created superficially and/or are as deep as about 1 mm in depth. The fractional ablative treatment treats the skin by ablating the treated tissue.

Combining each of the two treatment modalities enables single treatment coverage to extend to a higher percentage of coverage in a single treatment than what is
15 possible with either modality used alone. For example, combining fractional non-ablative treatments with fractional ablative treatments all within a single treatment session as disclosed herein enables results in a single treatment session that would normally take three or four separate non-ablative fractional treatment sessions. In addition, combining fractional non-ablative treatments with fractional ablative
20 treatments all within a single treatment session as disclosed herein enables results in a single treatment session that would normally take three or four or multiple separate ablative fractional treatment sessions. In addition, combining fractional non-ablative treatments with fractional ablative treatments all within a single treatment session as disclosed herein enables results in a single treatment session that would normally take
25 three or four or multiple separate ablative and/or non-ablative fractional treatment sessions. Further, combining the fractional non-ablative treatment with fractional ablative treatments as disclosed herein enables a higher percentage of overall coverage (i.e., percentage of tissue treated) without long term side effects (e.g., hyperpigmentation) then is possible with either treatment modality used alone.

30 In clinical testing, a fractional non-ablative treatment was combined with a fractional ablative treatment in accordance with the conditions and ranges described in Table 2.

- 44 -

Microfractional Handpiece	Type	Millijoules (MJ)	Area Coverage Range	Depth	Depth with PCA
Lux2940 TM	Fractional Ablative	5-24	10-30%	Up to about 1 mm	No data
Lux1440 TM	Fractional non-ablative	Up to 12	10-30%	300-400 micron	No data
Lux1540 TM	Fractional non-ablative	50-70	10-30%	1.0 mm	1.5 mm

Table 2

A fractional non-ablative treatment combines with a fractional ablative treatment
 to provide area coverage that ranges from about 20% to about 60% (see Table 1).
 Where each of the individual treatment modalities, fractional ablative and fractional
 non-ablative, is in the range of 25% to 30% coverage then each individual treatment
 modality is at or is very close to its own maximum and the area coverage ranges from
 about 50% to about 60%. Combining the two treatment modalities in this way enables
 in a single treatment a percentage of coverage called the combined coverage or the
 overall coverage (e.g., from about 50% to about 60%) that exceeds the maximum
 coverage for each of the individual treatment modalities. In some instances, the
 combination provides a maximum area coverage (e.g, 60%) that is double the available
 coverage of an individual treatment modality (e.g., where the fractional non-ablative
 maximum is 30%). If either fractional ablative or fractional non-ablative were
 individually used to provide 50% coverage in a single treatment there would be a high
 risk of hyper-pigmentation or hypo-pigmentation, however, by combining the two
 treatments to provide overall coverage of about 50% (25% from non-ablative fractional
 and 25% from ablative fractional) the risk of hyper-pigmentation or hypo-pigmentation
 is reduced.

Unlike fractional non-ablative employed alone, when combined with fractional
 ablative there can be some associated downtime. Generally, the downtime is the sum of
 the downtimes that would be required for each treatment modality used individually.
 For example, depending on the depth of treatment where the percentage of coverage

ranges from about 10% to about 40% the amount of downtime associated with a fractional ablative procedure ranges from about 2 days to 7 days. The fractional non-ablative portion of the treatment would not add to the associated downtime, accordingly, the downtime would depend only on the depth and the percentage of fractional ablative coverage and be determined no differently than if fractional ablation were used alone. Accordingly, the use of fractional non-ablative treatment in combination with the fractional ablative treatment does not add to the side effect of downtime associated with fraction ablative treatment.

At least some of the benefits of the combination of non-ablative fractional and ablative fractional treatment appear to be additive. For example, relative to fractional ablative used alone the combination with fractional non-ablative provides more density of coverage with less downtime (e.g., with fractional ablative treatment additional percentages of coverage is associated with increased downtime). The combination can enable collagen healing over a treatment area and/or a larger coverage area (e.g., including the non-ablative fractional portions) without as much downtime as is associated with higher coverage fractional ablative treatment.

Without being bound to a single theory, it is believed that use of fractional ablation initiates an intensive tissue healing response and the fractional non-ablative treatment portions take advantage of this healing response as well. The whole body works to heal both ablative and non-ablative treatment areas and the fractional ablative treatment initiates a more intense healing response, e.g. greater erythema and greater edema than is initiated by non-ablative fractional coagulation alone. Healing response refers to the degree of erythema and edema as well as the duration of the erythema and the edema prior to fully healed skin.

Combining fractional ablative treatment with fractional non-ablative treatment as disclosed herein can provide in a single treatment session similar results as previously achieved with fractional CO₂ treatment. The combined fractional ablative and fractional non-ablative treatment requires fewer days of downtime compared to fractional CO₂ treatment. Fractional CO₂ requires from about 6 days to about 7 days of downtime compared with the 4 days to about 5 days of downtime required when combining fractional ablative treatment with fractional non-ablative treatment as disclosed herein.

Use of ablative fractional treatment can enhance the delivery of topical treatments. The wounds created via fractional ablative treatments enable a topical to be delivered to the skin and/or the patient via the wounds. Suitable topical agents include, for example, wound healing compounds that can treat the open wounds created by the fractional ablative treatment. Optionally, the fractional ablative treatment areas may be employed for delivery of filler type compounds (e.g., restyline) into the void spaces that were created during the ablative fractional treatment.

Example Treatment 1:

The effects of non-ablative (e.g., coagulative) and ablative injury and their importance in an immediate skin tightening reaction are difficult to observe during fractional skin resurfacing procedures due to inflammatory skin reactions.

In one embodiment, a human ex vivo tissue model was developed and used to quantitatively examine skin tightening advantages for combining fractional ablative and fractional non-ablative treatments. Parameters based upon results from the model were then used in a clinical study for facial skin rejuvenation. Facial skin from rhytidectomies was treated with fractional ablation using the Palomar® Lux2940™ micro-fractional handpiece the facial skin was also treated with non-ablative fractional treatment using the Palomar® Lux1540™ micro-fractional handpiece and/or the Palomar® Lux1440™ micro-fractional handpiece under controlled temperature and hydration conditions.

Tissue shrinkage was quantified as a function of depth and density of fractional treatment. Safety, side effects, and effectiveness (Fitzpatrick Wrinkle Scale, 0-9, and quartile grading) with a minimum of 3 month follow-up were evaluated in patients (n=18) for facial rejuvenation using several combinations of fractional non-ablative and fractional ablative parameters with combined coverage reaching over 50%.

In the ex vivo model, the percent tissue shrinkage in an area was directly proportional to the density of treatment for both ablative and non-ablative modalities. Contraction in the 3rd dimension was substantial and related to the density and the depth of injury. When combined, the effects of both modalities were additive and combination settings suitable for clinical evaluations were observed to yield up to 30% tissue shrinkage. Patient treatments were well-tolerated with only topical anesthesia.

Occasional minimal bleeding and oozing was observed with rapid re-epithelialization. Erythema was longer-lasting than low coverage procedures but resolved with minimal complications using standard topical treatments.

5 Combination treatments employed approximately 25% fill or coverage for each treatment modality (e.g., 25% coverage with fractional non-ablative and 25% coverage with fractional ablative) of 150 to 300µm depths consistently resulted in over 75% improvement in skin texture and pigmentation in a single treatment with improved and reduced downtime compared to a high coverage fractional ablative-only procedure.

10 Combined high coverage deeper treatments from 300µm to 1mm for target deep periorbital, perioral and cheeks could achieve over 50% reduction in wrinkles with notable reduction in facial laxity with approximately ½ the downtime and discomfort of full-ablative procedures.

 Combined fractional non-ablative and fractional ablative treatments made higher
15 single treatment combined coverage (≥50%) possible and resulted in greater effectiveness than either modality alone. Combining these modalities offers new strategies for skin rejuvenation, which helps manage side effects and the downtime associated with fractional ablative-only procedures.

20 Example Treatment 2:

 In another embodiment, A new strategy to combine the coagulate damage from fractional non-ablative treatment with the ablative damage from a fractional ablative treatment was evaluated in an ex vivo model for skin shrinkage and in a clinical study for facial skin rejuvenation.

25 Facial skin from rhytidectomies was treated with fractional ablation using the Palomar® Lux2940™ micro-fractional handpiece the facial skin was also treated with non-ablative fractional treatment using the Palomar® Lux1540™ micro-fractional handpiece and/or the Palomar® Lux1440™ micro-fractional handpiece under controlled conditions.

30 Tissue shrinkage was quantified as a function of depth and density of fractional treatment. Safety, side effects, and effectiveness with a minimum of 3 month follow-up visits were evaluated in 18 patients for facial rejuvenation with combined fractional non-ablative and fractional ablative combined coverage reaching over 50%.

Skin tightening was observed in the ex vivo model that was directly proportional to both density and depth of treatment. When combined, the fractional ablative and fractional non-ablative effects were additive yielding up to 30% tissue shrinkage. At similar settings, patient treatments were well-tolerated with only topical anesthesia, had minimal bleeding and re-epithelialized within 4 days.

A single combination treatment employed approximately 25% fill or coverage for each treatment modality (e.g., 25% coverage with fractional non-ablative and 25% coverage with fractional ablative) at $<300\mu\text{m}$ depths resulted in over 75% improvement in skin texture, fine lines and pigmentation with acceptable side effects and downtime compared to lower coverage fractional ablative-only treatments. Combination treatments with column depths from $300\mu\text{m}$ to 1mm achieved over 50% reduction in wrinkles and notable reduction in facial laxity.

Combined fractional non-ablative and fractional ablative treatments made higher single treatment combined coverage ($\geq 50\%$) possible and resulted in greater effectiveness than either modality alone. Combining these modalities offers new strategies for skin rejuvenation which helps manage side effects and the downtime associated with fractional ablative-only procedures.

Example Treatment 3:

A 1540nm fractional non-ablative device employed a point compression array (PCA) optic that enhances the depth of coagulation and reduces epidermal damage. Such deep non-ablative fractional treatments were combined with a groove pattern of fractional ablation using an Er:YAG laser to determine maximum tolerable coverage with acceptable side effects and healing time. The goal was to identify a single treatment strategy to rejuvenate and tighten lax skin on the neck.

The treatments consisted of multiple passes with a 1540nm laser (i.e., a Palomar[®] Lux1540[™] micro-fractional handpiece) equipped with a point-compression-array optic followed by multiple passes with a Palomar[®] Lux2940[™] micro-fractional handpiece equipped with a groove pattern optic. The orientation of the parallel lines of ablation generated by the groove optic treatment was varied systematically. Subjects (n=12) received a single treatment coverage of 10- 30% for each device. Safety, side effects

and efficacy were evaluated with investigator assessments and standardized photographic grading.

5 Histology results from treatment with the Lux1540TM point compression array optics showed coagulation columns of 1.5mm depths. Lux2940TM treatments with groove optics generated channels up to 500 μ depths. Patient treatments were well-tolerated, had minimal bleeding and re-epithelialized within 4 days. Combination treatments with deep fractional coagulation and grooved ablation patterns demonstrated reduction in laxity with very good improvements in dyschromia and skin texture. Results
10 indicate that the combination of non-ablative fractional and ablative-fractional treatments allow higher coverage rates (40-50%) than are possible when either treatment modality is used alone with rapid healing and manageable side effects.

Combined deep dermal coagulation of non-ablative fractional treatment with the groove pattern of ablative fractional treatment resulted in significant rejuvenation and a
15 reduction in skin laxity. Combining these modalities enables new strategies to rejuvenate and tighten non-facial skin.

A disclosed herein, an applicator having one or more point compression element(s) that displace tissue fluid can enhance the depth of coagulation and reduce epidermal damage. By compressing or deforming skin or other tissue in relatively small
20 areas, the electromagnetic radiation ("EMR"), particularly optical radiation such as visible and infrared light, can be delivered to the tissue more effectively. For example, a quantity "A" of EMR can be delivered more deeply into a deformed area of the tissue than if the same area of tissue were not deformed and the quantity "A" of EMR e.g., the same amount of energy, were delivered. This phenomenon, is believed to be particularly
25 applicable to the fractional treatment of tissue with EMR. Use of one or more point compression element(s) provides local deformation of skin tissue using positive or negative pressure to enhance penetration of EMR during the fractional treatment of skin tissue. Without being bound to any single theory, it is believe that skin is compressible, but that tissue fluid (e.g., water) is not. Since skin comprises 60-70% water, then the
30 compressibility of skin arises in part from the displacement of tissue fluid (e.g., water). The deformed tissue accordingly has a modified tissue fluid (e.g., water) content that will change scattering and absorption. In addition to the changes in the optical properties of skin, the thermal properties also may change with compression. For example, with the

- 50 -

displacement of water, the average, local thermal properties such as thermal conductivity, specific heat, and thermal diffusivity will also change. These changes may combine to enhance desired thermal effects in compressed tissue arising from photothermolysis. For example, the adiabatic application of radiation to heat tissue to a desired temperature (e.g., for coagulation) will become possible at lower laser power levels where there is a decrease in thermal diffusivity of the tissue (with all other parameters the same).

Referring again to Formulas 1 and 2 disclosed and discussed herein, deformation of tissue (e.g., skin tissue) with one or more point compression element(s) can be altered to achieve desired diffusivity properties. In addition, the change in tissue fluid contact due to deformation can alter the tissue's scattering and absorption properties such that light can penetrate more deeply into the tissue compared to a treatment using the same energy and other parameters but lacking deformation of the tissue via one or more point compression elements.

Referring again to Figures 4-6, during treatment (Figure 5), the contact compression surface of the one or more point compression elements of an applicator are pressed into the surface of an area of tissue, in this case skin. The depth of deformation into the skin can range from about 100 microns to about 3 mm at the deepest point of deformation as compared to the normal surface of the non-deformed skin. The tissue is thereby deformed. While deformed, an array of beams of EMR, each having a diameter (d) and a pitch (l), is applied to the tissue. The array of EMR beams creates an array of treatment zones each having a treatment depth (h). The applicator is then removed from the tissue (Figure 6), and the tissue relaxes resulting in a treatment depth (H) for each treatment zone. Optionally, one or more of the array of points compression element(s) in the applicator is actively cooled for example, to a temperature of below -5°C. Any of a number of wavelength ranges may be emitted by the fractional beams, for example, the wavelength ranges can include: 1540 nm, 1440 nm, and 1208 nm.

Follicle Treatment

The current approach to managing hair growth and for hair removal is a uniform coverage approach, which leads to energy source(s) requiring high-power and high-

power-density. In some embodiments, point compression is employed for treating follicles for example for hair management by treating hair follicles. Other follicles, for example, sebaceous follicles may be treated in accordance with the disclosed methods, devices and systems. More specifically, in order to lessen the requirement for a high-power and high-power-density energy source; an approach employing non-uniform point compression coverage of the treatment area surface may be employed. In accordance with the methods and devices disclosed herein, follicles in a treatment area (e.g., hair follicles of unwanted hair and/or unwanted sebaceous follicles such as those related to acne) are treated by treating a treatment area including the follicles in a non-uniform manner. Such non-uniform methodologies can employ a set of treatment sub-areas separated from one another by untreated regions. Such non-uniform methodologies can also employ a set of higher intensity treatment sub-areas separated from one another by less intensely treated regions.

In one embodiment, treatment is electromagnetic radiation and non-uniform treatment coverage can have two or more treatment sub-areas separated from one another by one or more untreated regions or two or more treatment sub-areas separated from one another by regions treated at an with an electromagnetic radiation less than the electromagnetic radiation employed to treat the one or more treated sub-areas.

In one embodiment, treatment is irradiation fluence applied to and/or delivered to the tissue and non-uniform treatment coverage can have two or more treatment sub-areas separated from one another by one or more untreated regions. Alternatively, non-uniform treatment coverage can have two or more treatment sub-areas separated from one another by regions of tissue treated with an irradiation fluence less than the irradiation fluence delivered to the one or more treated sub-areas.

In one embodiment, treatment coverage creates one or more treatment effect occurring in response to application and/or delivery of electromagnetic energy. Treatment effect(s) can include, for example, tissue coagulation – full tissue coagulation or partial tissue coagulation, cell damage, cell modulation, tissue denaturation, and/or tissue modulation having a hyperthermic effect in response to electromagnetic energy. In one embodiment, non-uniform treatment coverage employs two or more treatment sub-areas separated from one another by one or more untreated regions. In one embodiment, only the treatment sub-areas are treated with electromagnetic radiation. In

another embodiment, non-uniform treatment coverage employs two or more treatment sub-areas separated from one another by treated regions where the treatment effect occurring in the treatment sub-areas is greater, larger, and/or more extensive than the treatment effect occurring in the treated regions that separate the treatment sub-areas. For example, in one embodiment, the hyperthermic effect in response to the application of electromagnetic energy is a treatment effect that is greater in the treatment sub-areas than the treatment effect that occurs in the treated regions that separate the treatment sub-areas.

The non-uniform treatment approach enables use of a lower-cost system due to the relatively low power energy source (and relatively low cost energy source) required by such a non-uniform approach.

In accordance with the methods and devices disclosed herein, treatment of sub-areas is employed to treat follicles such as hair follicles to manage unwanted hair. More specifically, the treatment includes treatment delivered to two or more treatment sub-areas (e.g., non-overlapping treatment sub-areas) separated from one another by untreated regions or regions treated at a level of intensity that is less than the intensity of treatment of the treatment sub-areas. More specifically, the treatment includes treatment delivered to two or more treatment sub-areas (e.g., non-overlapping treatment sub-areas) separated from one another by untreated regions or regions treated at an irradiation fluence that is less than the irradiation fluence delivered to the treatment sub-areas through, for example, the point compression elements. The dimensions of the individual treatment sub-areas are relatively small, having a smallest dimension across the smallest cross section of the treatment sub-area (e.g., the treatment effect and/or the damage in the treatment sub-area) that measures from about 0.1 mm to about 5 mm or from about 0.5 mm to about 3 mm. A relatively low power source can be sufficient to provide the required high power density in the treatment sub-areas that are surrounded by untreated tissue and/or tissue treated at a level of intensity, irradiation, fluence, and/or treatment effect that is less than the intensity, irradiation, fluence, and/or treatment effect of the treatment of the treated sub-areas.

Figures 21A, 21B and 21C each depicts treatment of a hair follicle located in skin 210 tissue 200. The hair follicle includes a hair 230, a hair bulge 240 located at a depth of about 2 mm in the tissue, and a hair bulb 250 located at a depth of about 6 mm

- 53 -

in the tissue. In each of Figures 21A, 21B and 21C treatment of the hair follicle is conducted with a different treatment device.

5 Figure 21A shows treatment with the treatment device 502, which is a device suitable for hair management that is placed on the skin 210 and treatment energy is delivered through the window 503. Delivery of the treatment energy from the window 503 is substantially uniform. The treatment energy scatters through the tissue 200 and in this way provides treatment energy to the hair bulge 240 and the hair bulb 250.

10 Figure 21B shows treatment with the treatment device 504, which is a device suitable for hair management that is placed on the skin 210 and is pressed against the skin 210 to provide some compression and displacement of the skin 210 tissue 200. Treatment energy is delivered through the window 505. Delivery of the treatment energy from the window 505 is substantially uniform. The treatment energy scatters through the tissue 200 and in this way provides treatment energy to the hair bulge 240 and the hair bulb 250.

15 Comparing Figures 21A and 21B, the energy provided by treatment device 504 is closer to the hair bulge 240 and the hair bulb 250 than the energy provided by the treatment device 502. The effectiveness of the energy delivery to the hair bulge 240 and hair bulb 250 is improved with the compression afforded by the treatment device 504 shown in Figure 21B compared to the treatment provided by treatment device 502, which is at surface of the skin (or above the surface of the skin) and is shown in Figure 21A.

20 Referring now to Figure 21C, the treatment device 500 is a device suitable for hair management that features an applicator 100 that has two or more point compression elements 110. The applicator 100 is placed on the skin 210 and is pressed against the skin 210 so that the two or more point compression elements 110 provide micro-deformation and displacement of the skin 210 tissue 200 (e.g., displacement of at least a portion of the fluid contained in the skin, such as, water, blood, or lymph). Displacement of skin improves penetration of the treatment energy into the skin 210 tissue 200. More specifically, displacement of the skin improves penetration of the treatment energy into the hair follicle (i.e., into the bulge 240 and the bulb 250 of the hair follicle) in the region of the skin 210 tissue 200.

- 54 -

In one embodiment, still referring to Figure 21C, treatment energy is delivered only through the point compression elements 110 (e.g., only through the contact compression surfaces of the two or more point compression elements). Delivery of the treatment energy only through the contact compression surfaces of the point compression elements can be accomplished by making solely the contact compression surfaces transparent (or optically transmissive) to the electromagnetic radiation suited to hair follicle treatment. The treatment energy (e.g., the electromagnetic radiation) can be pulsed through the contact compression surfaces of the point compression elements 110 or scanned over the surface of the applicator 100 but only enables to travel through the transmissive contact compression surfaces of the point compression elements 110. In the embodiment where the treatment energy is delivered only through the contact compression surfaces of the point compression elements the result is skin 210 tissue 200 with treated sub-areas surrounded by untreated areas of skin tissue.

In another embodiment, still referring to Figure 21C, treatment energy is delivered through the entire surface of the applicator 100 such that treatment energy is delivered to both the contact compression surfaces of the point compression elements 110 and through the regions of tissue surrounding the contact compression surfaces. In such an embodiment, all surfaces of the applicator 100 are transparent (or optically transmissive) to the electromagnetic radiation suited to hair follicle treatment. The treatment energy (e.g., the electromagnetic radiation) can be scanned over the surface of the applicator 100, however, the intensity of treatment of the tissue will differ with the portions of skin 210 tissue 200 adjacent to the contact compression surfaces having a higher intensity of treatment than the portions of tissue that surround the contact compression surfaces. The higher intensity of treatment at the treatment sub-areas adjacent the contact compression surfaces of the point compression elements 110 is due, at least in part, to improved penetration of treatment energy that is enabled due to the displacement of fluid in the skin 210 tissue 200 adjacent the point compression elements. The skin 210 tissue 200 that is treated by the portions of the applicator 100 adjacent the point compression elements 110 is treated with less intensity than the sub-areas adjacent the contact compression surfaces of the point compression elements. The energy delivered to the portions of the applicator 100 that surround the point compression elements 110 can contribute to treatment of the hair follicle, by scattering

within the skin 210 tissue 200 such that at least some of this energy that surrounds the treated sub-areas treats the hair follicle. In some embodiments, the treatment includes treatment delivered to two or more treatment sub-areas (e.g., non-overlapping treatment sub-areas) separated from one another by untreated regions or regions treated at a level of intensity, irradiation, fluence, and/or treatment effect that is less than the intensity, irradiation, fluence, and/or treatment effect of the treatment of the treated sub-areas.

In accordance with the non-uniform treatment methodologies (in which treatment is delivered to two or more treatment sub-areas that are separated from one another by untreated regions or are separated from one another by regions treated at a level of intensity that is less than the intensity of treatment of the treatment sub-areas) in some embodiments, in order to achieve the desired effect on a whole treatment area (e.g., removal of all unwanted hair or a target quantity of unwanted hair) multiple treatments may be utilized. By employing multiple separate treatments of a defined treatment area, a statistical overlap of the treated sub-areas leads to desired aesthetic effect, namely, treatment of all unwanted hair (or removal of a target quantity of unwanted hair) in the treatment region. An increased safety margin may be enjoyed in accordance with at least some of the disclosed methods, because the presence of untreated regions that surround the treated sub-areas of tissue will facilitate skin healing in the treated sub-areas of tissue, even in the case of severe skin damage in treatment sub-areas. In addition, the mechanical pressure provided by employing point compression elements during the course of treatment can reduce the perception of pain felt by the subject.

Multiple treatments with applicators having two or more point compression elements may be required to achieve the desired level of follicle treatment in a treatment area. For example, where hair follicles are being treated removal of all unwanted hair or a desired quantity of unwanted hair in a treatment area multiple treatments may be required to achieve the desired level of treatment in the treatment area. Formulas 3 and 4 together with Figure 22 provide an analytical model that may be employed to determine the number of treatments that is required to yield the desired level of treatment coverage at the diameter of the treatment zone. The analytical model requires that the diameter of the tissue treatment effect caused by the treatment at the targeted depth be determined (e.g., the depth of treatment damage). In the case of hair removal the depth of hair bulge and/or the depth of the hair bulb is the targeted depth or are the

targeted depth(s). The pitch of the point compression elements does not depend on the depth of treatment, but must also be known to determine the number of treatments required to achieve a desired level of treatment.

5 The coverage in a single treatment of a treatment area is determined by Formula

3. As used here a single treatment is where the applicator having two or more point
compression elements is pressed in contact with the skin to be treated and the treatment
device is fired so that energy is applied to the tissue through the applicator. The
treatment area is defined by the area of the tissue that falls inside the boundary of the
10 applicator of the treatment device.

Formula 3 shows the coverage in a single treatment where the treatment beams are assumed to be circular. Here D is the treatment diameter at the targeted depth and P is pitch of the point compression elements.

$$C1 = \frac{\pi \cdot D^2}{4 \cdot P^2},$$

(Formula 3)

Formula 4 provides an analytical model showing the number of treatments that are required (nt) to achieve the desired level of treatment referred to as the total coverage (CT) in view of the coverage achieved by a single treatment ($C1$).

$$nt = \frac{\ln(1 - CT)}{\ln(1 - C1)},$$

(Formula 4)

Figure 22 shows a plot with the number of treatments on the y-axis and the ratio of Diameter of treatment to Pitch on the x-axis. The solid line shows the relationship between the number of treatments and the diameter to pitch ratio to achieve 90% total coverage ($CT=0.9$). The dotted line shows the relationship between the number of treatments and the diameter to pitch ratio to achieve 80% total coverage ($CT=0.8$).

Figure 22 shows the higher the Diameter to Pitch ratio the fewer treatments are required to provide a relatively high total coverage.

The desired level of treatment (e.g., a total coverage from about 25% to about 100%) may be done in one day or over the course of several days or weeks. In some embodiments, the treatment is repeated or the treatments are repeated over the course of the hair growth cycle such that, for example, treatments are repeated in accordance with the cycle of hair growth of an area selected to be the treatment area.

In one embodiment, the treatment of unwanted hair by treated sub-areas is accomplished by scanning electromagnetic radiation over the treatment area. In another embodiment, the treatment of unwanted hair is a hybrid of a stamped and a scanned treatment technique. According to the hybrid stamped and scanned treatment technique the user places a device applicator on a treatment area. The treatment areas can be determined by, for example, the footprint of the treatment device (e.g., the window of the treatment device which can include the applicator 100 as disclosed herein). With the device applicator on the treatment area the device performs an internal scan that moves the scanned head between treatment sub-areas the treatment sub-areas are adjacent the contact compression surface of the point compression elements on the applicator. In one embodiment, the treatment device scans a pulse of electromagnetic energy to a first point compression element to create a treatment sub-area and then treatment device head moves to the adjacent point compression element to create a second treatment sub0area. In one embodiment, after the first scan is complete, the user stacks treatment by performing a second scan in the same treatment area, for example, without moving the treatment device from the location on the skin where it was originally place. In another embodiment, after the first scan is complete the user removes the treatment device from the skin and then places the treatment device applicator back in the treatment area, but in a different position. In another embodiment, after the scan is complete, the user places the treatment device applicator on, for example, another portion the skin thereby treating a separate treatment area to be treated according to the hybrid method.

Exemplary suitable device parameters include, for example, a wavelength of from about 400 nm to about 1200 nm, or from about 700 nm to about 1100 nm, or from about 780 nm to about 820 nm. The optical power can range from about 1 Watt to about 20 Watts, or from about 4 Watts to about 6 Watts. The pulse width can range from about 1 ms to about 100 ms, or from about 30 ms to about 50 ms. The fluence in a treatment sub-area can range from about 4 J/cm² to about 80 J/cm², or from about 20

J/cm² to about 50 J/cm². The coverage of skin tissue provided by the applicator in a single pass over a treatment area can range from about 1% to about 100 %, or from about 40% to about 60 %. In some embodiments, the surface of the skin has 100% coverage, however, the energy beam at the hair follicle depth (e.g., from about 1 mm to about 7 mm) becomes non-uniform, e.g., has less than 100% coverage due to energy beam attrition within the depth of the tissue. The spot size at the skin surface ranges from about 0.1 mm² to about 3 mm², or from about 0.5 mm² to about 2 mm².

In an exemplary embodiment, an 800 nm device uses 5 Watts of optical power delivered in 40 ms pulses to an active area of 0.5 mm², thus providing a fluence of 40 J/cm². Assuming 1 mm separation (pitch) between centers of neighboring treatment sub-areas, this configuration provides 50% coverage in single in a single pass (i.e., a single treatment with the applicator having point compression elements). Statistically, three to four treatments can provide 100% coverage. If movement between two firing positions takes 10 ms, 1 cm² of skin can be treated in about 5 seconds. Therefore, the treatment of the facial area (which measures about 100 cm²) will take about 8 minutes. In practice, such treatments can be repeated with a frequency of from about 1 time/week to about 7 times/week to achieve a cumulative effect that is uniform (e.g., treats all of the unwanted hair in a treatment area). In some embodiments, the treatments are repeated in accordance with the hair growth cycle such that treatment of unwanted hair in the treatment area occurs at the correct point in the growth cycle of the hairs in the treatment area.

A number of techniques can be used to increase efficiency and efficacy of treatment. Some efficiency and efficacy increasing techniques, which may be employed alone or in combination, include: (1) optimizing the beam geometry to increase penetration of the treatment energy in the target area, (2) use of two or more point compression elements to provide micro deformation to increase efficiency of energy delivery and/or to improve depth of energy delivery, (3) use of a smart technique in which the location of hair follicle(s) is determined using one or more diagnostic technique (e.g. an optical technique and/or an electrical technique) and the treatment device head and/or application is positioned to target a detected hair follicle, thus optimizing use of energy and reducing the treatment time. In some embodiments, due to

high coverage densities, neighboring treated sub-areas (e.g., neighboring treated areas) may touch or be in contact and/or even overlap.

5 The disclosed methods employing treatment of sub-areas (e.g., treating sub-areas adjacent untreated areas and treating sub-areas at a higher intensity than the treated surrounding areas) including employing point compression provide several advantages over traditional uniform coverage methods. Such advantages include requiring less power than currently available uniform coverage methods thereby providing a lower energy-source (e.g., light-source) cost, which can improve the manufacturing cost of
10 such systems (making home-use light-based hair management treatment products and home-use light based acne treatment products more likely than with the currently available higher power and higher cost energy source). The lower power requirements together with the non-uniform approach in which in one embodiment treated sub-areas of a treatment area are separated by untreated regions of the treatment area improve
15 safety provided by the disclosed method. The disclosed non-uniform approach in which in another embodiment treated sub-areas of a treatment area are treated with, for example, a greater level of intensity (e.g., achieving greater damage and/or a higher level of energy concentration) than the treatment of the regions that separate the sub-areas improves safety and/or efficacy.

20 In one embodiment, a device utilizes a high-power diode laser source emitting in the near infrared spectrum and is adapted for home use. In some embodiments, the device is battery powered. In some embodiments, the device is entirely hand held. The device can be configured for hair management and/or for acne management.

25 In one embodiment, where the device is configured for hair management a treatment area of skin including one or more hair follicles is treated by treating sub-areas separated by hair follicles that are not treated in the treatment. The non-uniform hair management method can optionally employ point compression of the treatment area. In some embodiments, the hair management device provides uniform hair treatment by, for example, employing multiple treatments of the treatment area.

30 The hair management device typically couples light to the skin through a treatment window, the window having an area of approximately 1 cm^2 . The peak optical power at the treatment window is typically in the range of about 10W to about 100W, this peak optical power range allows fluences in the range of about 5 to about 20 J/cm^2

- 60 -

to be produced with pulse durations on the order of 10's to 100's of ms. This fluence range is useful for hair growth management.

5 To treat an area, the user simply places the treatment device window in contact with the user's skin. Generally, the treatment area falls within (e.g., inside) the boundary of the window of the treatment device. In one embodiment, the device fires the laser when skin contact is detected by a contact sensor located in one or more region of the perimeter of the treatment window. In some embodiments, the device automatically fires the laser when skin contact is detected. As discussed here, each time
10 the device fires the laser is referred to as "a treatment" of the treatment area. The user then lifts and moves device and places the treatment window on an adjacent area of the skin to another treatment area and once contact between the treatment window and the skin is detected the device may be fired by the user and/or be automatically fired upon detection of contact. In this way the user repeats the process to treat their skin. In one
15 embodiment, the light distribution at the treatment window is uniform, which allows the user to maximize the treatment fluence of the treatment area of skin in contact with the window.

To convert distribution of light provided to the skin by the treatment window from the uniform distribution to a pattern of treatment sub-areas (or treated sub-areas),
20 an applicator having two or point compression elements may be employed. In one embodiment, two or more treatment sub-areas surrounded by portions of skin that are not treated by the treatment device in the treatment. In another embodiment, the two or more treatment sub-areas are treated at an intensity that is greater than the intensity of treatment of the portions of skin that surround the treatment sub-areas, in this way
25 during the treatment effect (e.g., such as the damage to the tissue) at the treatment sub-areas is greater than the treatment effect that surrounds the treatment sub-areas. In some embodiments, the applicator is an optic that is detachably coupled to the treatment window and the optic converts the uniform light distribution to two or more treated sub-areas. The separate optic may be an applicator such as the applicator 100 including two
30 or more point compression elements described in relation to Figures 1-7 and 8.

The optic (e.g., applicator) can be made from any of a number of materials. Suitable materials include dielectrics, ceramics, sapphire, diamond, quartz, polymers, glass, Lucite, and crystals, for example. In an embodiment where the applicator is an

- 61 -

optic designed for use as a disposable (i.e., for use a limited number of times including single-use) the applicator may be made from optical-grade plastic, for example.

Applicator disposability may be desirable because during use debris such as lotion, hair and skin may be collected on and/or between the point compression elements.

In one embodiment, the optic (e.g., the applicator 100) is reversibly attached to a hand-held treatment device by an adhesive disposed on one side of the applicator. The other side of the applicator has two or more point compression elements, specifically, the other side of the applicator has nine point compression elements each point compression element has the shape of a beam-forming prism (e.g, a triangular prism with a truncated apex and each truncated apex is a contact compression surface that contacts the skin in the treatment area). The optic converts the uniform distribution provided by the treatment device to a fractional pattern. Optionally, the optic is designed for single use and is disposable and it is made from optical-grade plastic.

Figure 23 shows the distribution of light into tissue 200 (i.e., dermis tissue) produced by an applicator having nine point compression elements. The applicator (including the point compression elements) is made from acrylic material. More specifically, the light distribution shown in Figure 23 is produced when the attachment 100 is a reversibly attached optic having nine point compression elements where the entire optic (e.g., the applicator) is optically transmissive to electromagnetic radiation and the optic is attached to the treatment window of the treatment device. Each of the point compression elements employed to make the light distribution shown in Figure 23 has a shape similar to that shown in Figure 1B. The height of each point compression element is about 2 mm and the contact compression surface of each point compression element has a square area of about 1 mm^2 . Treatment zone(s) of damaged and/or treated tissue 310 (i.e., treated sub-areas 310) are created in the tissue 200 with the aid of point compression elements and the contact compression surface that is in contact with the tissue 200 during an electromagnetic radiation emission. The treatment zone(s) of damaged and/or treated tissue 310 (i.e., treated sub-areas) are more intensely treated (i.e., more intensely damaged) than the damaged and/or treated tissue 305 that was treated in the absence of contact with the contact compression surface of the point compression element(s) during the electromagnetic radiation emission. The intensity shown in the square spots is of the treated sub-areas (i.e., 310) is where the contact compression surface of the nine point

- 62 -

compression elements contacted the subject's dermis during treatment. The peak intensity of the emission delivered during the treatment of the tissue 200 is at the nine contact compression surfaces that create the treated sub areas 310. The intensity of the treated tissue 310 that contacted the contact compression surface of the point compression elements during treatment ranges from about 25% to about 35% higher than the average intensity provided by the remaining portions of the applicator during the treatment.

Referring to Figure 24, in one embodiment, an applicator 100 comprising one or more point compression elements 110 is disposed on a treatment device 500. The applicator 100 may be detachably attached to the treatment device 500 by any suitable method including, for example, adhesive, magnetism, mechanical means, etc. Alternatively, the applicator 100 is permanently attached to the treatment device 500, for example, the applicator 100 can be an integral part of the treatment window of the treatment device 500. The skin 210 tissue 200 contains one or more hair follicles, which includes the hair bulge 240, the hair bulb 250 and a hair shaft 230. The hair 230 may or may not be protruding through the skin 210 from the hair follicle. In some embodiments, the skin 210 tissue 200 contains follicles including hair follicles (that are the source of unwanted hair) and sebaceous follicles that are the source of unwanted sebum oil and/or acne. The one or more follicles may be treated by the treatment device 500 (including the applicator 100 having two or more point compression elements 110) for follicle management (e.g., hair growth management and/or acne management). All or a portion of the follicle may be within the tissue 200 at a depth ranging from about 0.5 mm to about 10 mm, or from about 1 mm to about 7 mm, or from about 1 mm to about 2 mm.

Referring still to Figure 24, each point compression element 110 has a contact compression surface that contacts the skin 210. In accordance with follicle treatment, the applicator 100 is at least partially transparent to an electromagnetic radiation beam having a wavelength range of from about 290 nm to about 11000 nm, having a fluence of from about 0.1 J/cm² to about 1000 J/cm², and having a pulse width of from about 1 nanosecond to 20 seconds. In another embodiment, the applicator 100 is at least partially transparent to an electromagnetic radiation beam having a wavelength range of from about 400 nm to about 2700 nm, having a fluence of from about 1 J/cm² to about

- 63 -

200 J/cm², and having a pulse width of from about 1 nanosecond to 20 seconds. In one embodiment, the entire applicator 100, including the point compression element(s) 110, and the portions of the applicator 100 between point compression element(s) 100 is
5 transparent to the electromagnetic radiation beam.

The applicator 100 compresses the skin 210 and tissue 200 in contact with the contact compression surface(s) of the point compression element(s) 110 of the applicator 100. The skin 210 includes extracellular fluid, water, blood, lymph, pus, etc. The contact compression surface(s) of the point compression element(s) 110 displace skin in
10 contact with the contact compression surface(s). In some embodiments, the contact compression surface(s) displace the skin 210 by at least 0.2 mm. In some embodiments, the displacement of skin 210 can range from about 0.2 mm to about 3 mm or from about 0.5 mm to about 3 mm. In some embodiments, the contact compression surface(s) of the point compression element(s) 110 of the applicator 100 are pressed against the skin 210
15 for a period of time to allow all or a portion of the fluid in the skin (e.g., one or more of extracellular fluid, water, blood, lymph, pus etc.) to be displaced due to contact with the contact compression surface(s) of the point compression element(s). The period of time for the fluid in the skin to be displaced can range from about 0.1 second to about 1 minute, for example. Displacement of all or a portion of the fluid in the skin from the
20 contact compression surface(s) of the point compression element(s) improves the effectiveness of treatment with the treatment energy (e.g., electromagnetic radiation).

Referring still to Figure 24, in one embodiment, the applicator 100 having point compression elements 110 is a substantially permanent part of the treatment device 500 such that it provides the output window to the treatment device 500. The contact
25 compression surfaces of the point compression elements 110 compress the skin 210 and tissue 200 where the contact compression surfaces are pressed into the surface of the skin 210 thereby deforming the skin 210 and tissue 200. In one embodiment, a scanned head 510 is moving within the treatment device 500. For example, the scanned head 510 moves in the lateral plane inside the treatment device 500. The energy source 520
30 supplies energy (e.g., electromagnetic radiation) to the scanned head 510. The guide 530 can direct the pattern of the scanned head 510. The scanning mechanism 540 controls the motion of the scanned head 510.

In one embodiment, the contact compression surfaces of the point compression elements 110 correspond to firing positions of the scanned head 510. For example, the energy source delivers a pulse of directed energy 550 to the tissue 200 only once the scanned head 510 aligns with the contact compression surface of a point compression element 110. Thus, in such an embodiment, the treatment device 500 delivers successive pulses of directed energy 550 (e.g., electromagnetic energy) to the skin 210 tissue 200 only when the scanned head 510 is aligned with the contact compression surface of each point compression element 110. Thus, as shown schematically in Figure 24, the scanned head 510 is expected to align with the contact compression surface of five point compression elements 110 and deliver five separate successive pulses of directed energy 550 one pulse to each of the five contact compression surfaces of the five point compression elements 110.

In another embodiment, the scanned head 510 provides substantially constant radiation (e.g., continuous wave radiation). In such an embodiment, the scanned head 510 is moved across the applicator 100 while constantly (or substantially constantly) delivering radiation. In embodiments where all of the applicator 100 is optically transmissive to or at least partially transparent to the electromagnetic radiation then the skin 210 and tissue 200 adjacent to the scanned head 510 will be treated with the directed energy. It is expected that the portions of the skin 210 tissue 200 in contact with the contact compression surface(s) of the point compression elements 110 will be areas of higher intensity of damage (or areas of greater tissue treatment effect, or areas of greater fluence delivery) compared to the portions of the skin tissue 200 in contact with the other portions of the applicator 100. Referring still to Figure 24, optionally, only the contact compression surface(s) of the point compression element(s) 110 are optically transmissive to or at least partially transparent to the electromagnetic radiation, in such embodiments, only the portions of the skin 210 tissue 200 in contact with the contact compression surface(s) will be treated. In some embodiments, each contact compression surface of each point compression element 110 has a size larger than the electromagnetic radiation beam delivered therethrough.

Figures 25A and 25 B shows an applicator 1100, the applicator 1100 has two or more point compression elements 1110 in the form of truncated pyramids. The point compression elements 1110 form a two-dimensional array. When the applicator 1100 is

mounted to or disposed on the treatment device handpiece 1500 the base(s) of the point compression element 1110 “pyramids” are disposed on the window 1503 of the treatment device hand piece 1500. The applicator may be made of any of a number of materials (including plastic or optical glass) optically transmissive and/or transparent to the wavelength range of the handpiece 1500. Each point compression element 1110 has a bottom face that is a square having one side that measure from about 3 mm to about 5 mm, the point compression element height is about 3 mm and contact compression surface is a square having one side that measures about 1 mm. The applicator keeps all of the point compression elements in the desired array (i.e., fuses them together). Spaces or gaps are present between the point compression elements 1110 at base of the applicator. The applicator 1100 is attached to the top of the hand piece 1500. In one embodiment, the hand piece 1500 is an IPL and the applicator 1100 is attached (reversibly and/or permanently) to the waveguide 1503 of the hand piece. In one embodiment, the applicator 1100 is mounted to the waveguide 1503 of the hand piece 1500 using optical cement that is transparent to the operational wavelength and has a refractive index that lessens and/or minimizes Fresnel losses at the waveguide 1503/applicator 1100 junction.

In another embodiment, the applicator 1100 is reversibly attached to the waveguide 1500 by employing one or more mechanical device such as a latch to mechanically secure the applicator 1100 to the waveguide 1503 of the hand piece 1500. In some embodiment, an optical gel is disposed between the waveguide 1503 and the applicator 100 to lessen and/or to minimize Fresnel losses at the junction there between. Suitable methods of reversible attachment of the applicator 1100 to the hand piece 1500 include mechanical, magnetic or vacuum coupling methods.

Figures 25C and 25D depict optional applicators 1100B and 1100C each having point compression elements 1110B, 1110C in the shape of a rectangle. Treatment of follicles including hair follicles with the applicators 1100B and 1100C can provide coverage at the depth of treatment that has the form of a stripe of treatment (e.g., a stripe of damage).

Referring now to Figure 26, in one embodiment, point compression elements 1110C are disposed on the perimeter of a cylinder 1000C. The point compression elements 1110C are arranged around the perimeter of a cylinder 1000C. In one

- 66 -

embodiment, a flashlamp 1520 is located on an inside surface of the cylinder 1000C, e.g., in the center of the cylinder 1000C. A reflector 1570 couples the flashlamp1520 light to the point compression element(s) 1110C. During use for treatment of skin 210 the cylinder 1000C is rotated along the skin 210 and in one embodiment the flashlamp1520 is synchronized to fire directed energy only when one or more (e.g., two or more or a row of) point compression elements 1110C are in contact with skin.

Figure 27A shows a pinched portion of skin 210 tissue 200 having a hair follicle including a bulge 240, a bulb 250 and a hair 230. The pinched portion of tissue can be located on any number of skin tissue sites in a subject's body. For example, the pinched portion of tissue can be in the region of an eyebrow.

Figure 27B shows the pinched portion of skin 210 tissue 200 having a hair follicle including a bulge 240, a bulb 250 and a hair 230. The hair follicle is being treated with electromagnetic radiation through an applicator having opposing point compression elements.

Figure 27C shows the pinched portion of skin 210 tissue 200 having a hair follicle including a bulge 240, a bulb 250 and a hair 230. The hair follicle is being treated with electromagnetic radiation through an applicator having offset point compression elements. Referring to Figures 27A-27C, the pinched portion of skin may be gathered into a pinched portion by any suitable means including, for example, by mechanical force or by vacuum force, for example. Applicators suited to treating a pinched portion of skin may have, for example, a v-shape, a u-shape and/or a c-shaped body with the point compression element(s) disposed on one surface of the applicator.

This disclosure incorporates by reference all of the disclosure in United States Patent Nos. 5,595,568 entitled "Permanent Hair Removal Using Optical Pulses" and 5,735,844 entitled "Hair Removal Using Optical Pulses." United States Patent Publication No. US 2008-0058783 entitled "Handheld Photocosmetic Device" and in United States Patent Publication No. US 2004-0147984 entitled "Method and Apparatus for Delivering Low Power Optical Treatments" and in United States Patent Application Serial No. 12/405,931 entitled "Method and Apparatus for Fractional Deformation and Treatment of Tissue" filed on March 17, 2009.

Equivalents

While only certain embodiments have been described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope as defined by the appended claims. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the appended claims.

References and Definitions

The patent, scientific and medical publications referred to herein establish knowledge that was available to those of ordinary skill in the art. The entire disclosures of the issued U.S. patents, published and pending patent applications, and other references cited herein are hereby incorporated by reference.

All technical and scientific terms used herein, unless otherwise defined below, are intended to have the same meaning as commonly understood by one of ordinary skill in the art. References to techniques employed herein are intended to refer to the techniques as commonly understood in the art, including variations on those techniques or substitutions of equivalent or later-developed techniques which would be apparent to one of skill in the art. In addition, in order to more clearly and concisely describe the claimed subject matter, the following definitions are provided for certain terms which are used in the specification and appended claims.

Numerical Ranges

As used herein, the recitation of a numerical range for a variable is intended to convey that the embodiments may be practiced using any of the values within that range, including the bounds of the range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently

discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values ≥ 0 and ≤ 2 if the variable is inherently continuous. Finally, the variable can take multiple values in the range, including any sub-range of values within the cited range.

5 As used herein, unless specifically indicated otherwise, the word "or" is used in the inclusive sense of "and/or" and not the exclusive sense of "either/or."

 As used herein, EMR includes the range of wavelengths approximately between 200 nm and 10 mm. Optical radiation, i.e., EMR in the spectrum having wavelengths in the range between approximately 200 nm and 100 μm , is employed in some of the
10 embodiments described above, but, also as discussed above, many other wavelengths of energy can be used alone or in combination. The actual spectrum may also include broad-band components, either providing additional treatment benefits or having no effect on treatment. Additionally, the term optical (when used in a term other than term "optical radiation") applies to the entire EMR spectrum. Other energy may be used to for
15 treatment islets in similar fashion. For example, sources such as ultrasound, photo-acoustic and other sources of energy may also be used to form treatment islets. Thus, although the embodiments described herein are described with regard to the use of EMR to form the islets, other forms of energy to form the islets are within the scope of the invention and the claims.

CLAIMS

What is claimed is:

- 5 1. A method of follicle treatment, the method comprising the steps of:
 selecting a treatment area of skin for follicle treatment, the treatment area
 comprising a plurality of follicles;
 pressing contact compression surfaces of two or more point compression
 elements to the treatment area;
- 10 displacing skin in contact with the contact compression surfaces by at least about
 0.2 mm;
 delivering radiation in the wavelength range of from about 400 nm to about 2700
 nm, having fluence of from about 1 J/cm^2 to about 200 J/cm^2 , and having a pulse width
 of from about 1 nanosecond to about 20 seconds through at least the contact
- 15 compression surfaces.
2. The method of claim 1 wherein the contact compression surfaces have at least
 one dimension that ranges from about 0.5 mm to about 5 mm
- 20 3. The method of claim 1 wherein the contact compression surfaces have at least
 one dimension that ranges from about 0.5 mm to about 3 mm.
4. The method of claim 1 wherein the radiation is delivered solely through an inner
 perimeter of the contact compression surfaces.
- 25 5. The method of claim 4 wherein the radiation is delivered in successive pulses,
 each successive pulse of radiation being delivered through the inner perimeter of each of
 the contact compression surfaces.
- 30 6. The method of claim 1 wherein the radiation is delivered in successive pulses,
 each successive pulse of radiation being delivered through each of the contact
 compression surfaces.

- 70 -

7. The method of claim 1 wherein the plurality of follicles comprise hair follicles.
8. The method of claim 1 wherein the plurality of follicles comprise sebaceous
5 follicles.
9. An applicator for creating point compression of tissue, the applicator comprising:
two or more point compression elements, the two or more point compression
elements each having a contact compression surface, the contact compression surfaces
10 having at least one dimension that ranges from about 0.5 mm to about 5 mm, the
applicator being at least partially transparent to an electromagnetic radiation beam
having a wavelength range of from about 290 nm to about 11000 nm, having a fluence
of from about 0.1 J/cm^2 to about 1000 J/cm^2 , and having a pulse width of from about 1
nanosecond to about 20 seconds.
- 15 10. The applicator of claim 9 the applicator being at least partially transparent to a
wavelength range of from about 400 nm to about 2700 nm, having a fluence of from
about 1 J/cm^2 to about 200 J/cm^2 , and a pulse width of from about 1 nanosecond to
about 20 seconds.
- 20 11. The applicator of claim 9 further comprising a mechanism of attachment to
attach the applicator to a treatment device configured to deliver electromagnetic
radiation.
- 25 12. The applicator of claim 11 wherein the mechanism of attachment is at least one
of an adhesive or a magnet.
13. The applicator of claim 11 wherein the mechanism of attachment is a
mechanical device.
- 30 14. The applicator of claim 9 comprising an identifier that indicates the compatibility
of the applicator with a treatment device.

- 71 -

15. The applicator of claim 9 comprising an identifier that indicates the presence or absence of the applicator to a treatment device.

5 16. The applicator of claim 9 wherein solely the contact compression surfaces are partially transparent to the electromagnetic radiation, wherein each contact compression surfaces has a size larger than the electromagnetic radiation beam delivered therethrough.

10 17. An apparatus for performing a treatment on tissue, comprising:
a) a treatment device configured to deliver successive pulses of electromagnetic radiation, the device having an electromagnetic radiation source;
b) an applicator for creating point compression of tissue, the electromagnetic radiation source being in communication with the applicator, the applicator having two
15 or more point compression elements, the two or more point compression elements each having a contact compression surface, the contact compression surfaces having at least one dimension that ranges from about 0.5 mm to about 5 mm, the applicator being configured to deliver each successive pulse of electromagnetic radiation through each contact compression surface during operation, wherein each contact compression surface
20 has a size larger than the electromagnetic radiation beam delivered therethrough.

18. The apparatus of claim 17 the applicator further comprising a mechanism of attachment to attach the applicator to the treatment device.

25 19. The apparatus of claim 18 wherein the mechanism of attachment is at least one of an adhesive or a magnet.

20. The apparatus of claim 18 wherein the mechanism of attachment is a mechanical device.

30

- 72 -

21. The apparatus of claim 17 wherein the successive pulses of electromagnetic radiation have a wavelength range of from about 400 nm to about 2700 nm, have a fluence of from about 1 J/cm² to about 200 J/cm², and have a pulse width of from about 1 nanosecond to about 20 seconds.

22. An apparatus for performing a treatment on tissue, comprising:
a) a treatment device the device having an electromagnetic radiation source configured to deliver electromagnetic radiation;
b) an applicator for creating point compression of tissue, the electromagnetic radiation source being in communication with the applicator, the applicator having two or more point compression elements, the two or more point compression elements each having a contact compression surface, the contact compression surfaces having one dimension that ranges from about 0.5 mm to about 5 mm, the applicator being configured to deliver electromagnetic radiation therethrough.

23. The apparatus of claim 22 wherein the applicator is permanently attached to the treatment device.

24. The apparatus of claim 22 wherein the electromagnetic radiation has a wavelength range of from about 400 nm to about 2700 nm, a fluence of from about 1 J/cm² to about 200 J/cm², and a pulse width of from about 1 nanosecond to about 20 seconds.

FIG. 1A




FIG. 2




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G




FIG. 1H




FIG. 1I




FIG. 1J




FIG. 1K




FIG. 1L




FIG. 3




FIG. 4
BEFORE TREATMENT




FIG. 5
DURING TREATMENT




FIG. 6
AFTER TREATMENT




FIG. 7





FIG. 8



5 / 20

FIG. 9




FIG. 10




FIG. 11




FIG. 12





FIG. 13
EXPERIMENTAL SET UP

100



8 / 20

FIG. 14





FIG. 15



9 / 20

FIG. 16A
COLUMN DEPTH USING CONTACT ALONE

400 mcm FIBER/ 200 mJ/ 1540 nm



FIG. 16B
COLUMN DEPTH USING 1 mm DEFORMATION

400 mcm FIBER/ 200 mJ/ 1540 nm



10 / 20

FIG. 17




FIG. 18




FIG. 19A




FIG. 19B




FIG. 19C






FIG. 20A



8 mJ
Depth= 320 microns
Diameter= 150 microns
Volume= x

* ALL 30% SURFACE COVERAGE


FIG. 20B



70 mJ
Depth= 600 microns
Diameter= 400 microns
Volume= 2x

* ALL 30% SURFACE COVERAGE

FIG. 20C



70 mJ
Depth= 860 microns
Max Diameter= 400 microns
Volume= 4x

* ALL 30% SURFACE COVERAGE

FIG. 21A




FIG. 21B





FIG. 21C






FIG. 22




FIG. 23




FIG. 24




FIG. 25A






FIG. 25B








FIG. 26

FIG. 27A




FIG. 27B




FIG. 27C

